<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006517.pub3" GROUP_ID="HIV" ID="785306120612352370" MERGED_FROM="" MODIFIED="2011-01-20 00:05:53 +0100" MODIFIED_BY="Tara Horvath" REVIEW_NO="" REVMAN_SUB_VERSION="5.0.25" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.2">
<COVER_SHEET MODIFIED="2011-01-20 00:05:53 +0100" MODIFIED_BY="Tara Horvath">
<TITLE MODIFIED="2010-05-12 11:21:31 -0700" MODIFIED_BY="Tara Horvath">Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy</TITLE>
<CONTACT MODIFIED="2011-01-20 00:05:53 +0100" MODIFIED_BY="Tara Horvath"><PERSON ID="037B033282E26AA2005EE6A64B94CA5C" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Eliza</FIRST_NAME><MIDDLE_INITIALS>H</MIDDLE_INITIALS><LAST_NAME>Humphreys</LAST_NAME><EMAIL_1>elizahumphreys@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Global Health Sciences</DEPARTMENT><ORGANISATION>University of California, San Francisco</ORGANISATION><ADDRESS_1>50 Beale Street</ADDRESS_1><ADDRESS_2>Suite 1200</ADDRESS_2><CITY>San Francisco</CITY><ZIP>94105</ZIP><REGION>California</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>415-597-8208</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-01-20 00:05:53 +0100" MODIFIED_BY="Tara Horvath"><PERSON ID="037B033282E26AA2005EE6A64B94CA5C" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Eliza</FIRST_NAME><MIDDLE_INITIALS>H</MIDDLE_INITIALS><LAST_NAME>Humphreys</LAST_NAME><EMAIL_1>elizahumphreys@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Global Health Sciences</DEPARTMENT><ORGANISATION>University of California, San Francisco</ORGANISATION><ADDRESS_1>50 Beale Street</ADDRESS_1><ADDRESS_2>Suite 1200</ADDRESS_2><CITY>San Francisco</CITY><ZIP>94105</ZIP><REGION>California</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>415-597-8208</PHONE_1></ADDRESS></PERSON><PERSON ID="17038" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Larry</FIRST_NAME><MIDDLE_INITIALS>W</MIDDLE_INITIALS><LAST_NAME>Chang</LAST_NAME><SUFFIX>MD, MPH</SUFFIX><POSITION>Assistant Professor of Medicine</POSITION><EMAIL_1>larrywillchang@gmail.com</EMAIL_1><EMAIL_2>lchang@alum.emory.edu</EMAIL_2><ADDRESS><DEPARTMENT>Division of Infectious Diseases, Department of Medicine</DEPARTMENT><ORGANISATION>Johns Hopkins School of Medicine</ORGANISATION><ADDRESS_1>1503 East Jefferson St.</ADDRESS_1><ADDRESS_2>Room 116</ADDRESS_2><CITY>Baltimore</CITY><ZIP>21287</ZIP><REGION>MD</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 410 929 2001</PHONE_1><FAX_1>+1 410 685 0031</FAX_1></ADDRESS></PERSON><PERSON ID="0243E10F82E26AA2019CE8F3A590A056" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jamal</FIRST_NAME><LAST_NAME>Harris</LAST_NAME><EMAIL_1>HarrisJ@peds.ucsf.edu</EMAIL_1><ADDRESS><DEPARTMENT>Department of Pediatrics</DEPARTMENT><ORGANISATION>University of California, San Francisco</ORGANISATION><CITY>San Francisco</CITY><ZIP>94143</ZIP><REGION>California</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>415-597-8200</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2011-01-06 12:06:32 -0800" MODIFIED_BY="Angela Broad">
<UP_TO_DATE>
<DATE DAY="1" MONTH="4" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="12" MONTH="7" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="12" MONTH="5" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="6" YEAR="2010"/>
</DATES>
<WHATS_NEW MODIFIED="2011-01-19 15:04:53 -0800" MODIFIED_BY="Tara Horvath">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-01-19 15:04:53 -0800" MODIFIED_BY="Tara Horvath">
<DATE DAY="19" MONTH="1" YEAR="2011"/>
<DESCRIPTION>
<P>Typo fixed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-01-19 15:03:58 -0800" MODIFIED_BY="Tara Horvath">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2011-01-19 15:03:54 -0800" MODIFIED_BY="Tara Horvath">
<DATE DAY="12" MONTH="5" YEAR="2010"/>
<DESCRIPTION>
<P>New citation.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-01-19 15:03:58 -0800" MODIFIED_BY="Tara Horvath">
<DATE DAY="12" MONTH="5" YEAR="2010"/>
<DESCRIPTION>
<P>First update of the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2011-01-06 12:07:05 -0800" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2010-05-12 11:24:53 -0700" MODIFIED_BY="Tara Horvath">
<SOURCE MODIFIED="2010-05-12 11:24:53 -0700" MODIFIED_BY="Tara Horvath">
<NAME>Global Health Sciences, University of California, San Francisco</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2011-01-06 12:07:05 -0800" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2010-05-12 11:25:19 -0700" MODIFIED_BY="Tara Horvath">
<NAME>Centers for Disease Control and Prevention (CDC)</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION>
<P>USA Cooperative Agreement #U2GPS001468, "Atlanta HQ UCSF Technical Assistance to Support the President's Emergency Plan for AIDS Relief" from the Centers for Disease Control and Prevention (CDC), with funds from National Center for HIV, Viral Hepatitis, STDs and TB Prevention (NCHSTP). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of CDC.</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2011-01-06 12:07:05 -0800" MODIFIED_BY="[Empty name]">
<NAME>World Health Organization</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION>
<P>World Health Organization #200106621, Systematic reviews and development of GRADE profiles, based on the new WHO GRC guidelines, for the "WHO Guidelines on antiretroviral therapy for HIV infection in adults and adolescents - 2009 revision."</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-05-12 15:18:14 -0700" MODIFIED_BY="Tara Horvath">
<SUMMARY MODIFIED="2010-05-11 16:47:15 -0700" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-12-10 06:20:35 -0800" MODIFIED_BY="[Empty name]">Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy</TITLE>
<SUMMARY_BODY MODIFIED="2010-05-11 16:47:15 -0700" MODIFIED_BY="[Empty name]">
<P>Highly active antiretroviral therapy (HAART) has greatly reduced the illness and deaths of HIV-infected people worldwide. There are many options for first-line antiretroviral therapy (ART), but second-line therapy is necessary for people who fail the first-line treatment. This review attempted to assess the best ART regimen for HIV-infected people in low- and middle-income countries following treatment failure; however, the review found limited studies addressing this topic. One randomised trial and one abstract of an observational study evaluated whether or not to maintain lamivudine in second-line regimens; both suggested no difference in outcomes. There were no studies comparing boosted PI-containing second-line regimens in patients failing an NNRTI-based first-line regimen, nor any evaluating NRTI combinations after first-line with non-thymidine analog combinations. While such trials are difficult to conduct for a variety of reasons, randomised controlled trails comparing second-line therapies are needed, especially in resource-limited settings.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-05-11 17:29:08 -0700" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2010-01-08 08:22:15 -0800" MODIFIED_BY="[Empty name]">
<P>Highly active antiretroviral therapy has reduced the morbidity and mortality of patients with HIV/AIDS. A common first-line ART regimen in low-resource settings includes a non-nucleoside reverse transcriptase inhibitor (NNRTI) and two nucleoside reverse transcriptase inhibitors (NRTIs). If treatment failure occurs, a change to second-line therapy is necessary.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2010-04-16 09:50:16 -0700" MODIFIED_BY="[Empty name]">
<P>This systematic review aimed to assess the optimum antiretroviral regimen for patients with HIV who fail first-line therapy (ART-naive) with a recommended World Health Organization (WHO) first-line regimen.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-12-10 06:19:57 -0800" MODIFIED_BY="[Empty name]">
<P>Electronic databases and conference proceedings were searched with relevant search terms without limits to language.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-12-17 18:30:44 -0800" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials of HIV-infected adolescent and adult patients administered second-line ART after virologic failure of a first-line regimen were included. Observational studies were included given the insufficient number of trials identified. The primary outcome measure included mortality. Secondary outcome measures included rate of adverse events, change in mean CD4 cell count, clinical resolution of symptoms, proportion of patients achieving undetectable viral load (VL) and acquisition of genotypic mutations.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-04-15 07:09:05 -0700" MODIFIED_BY="[Empty name]">
<P>Two authors assessed each reference for inclusion and exclusion criteria established <I>a priori</I>. Data were abstracted independently using a standardised abstraction form. Risk of bias was assessed for individual studies and the GRADE approach for assessing the quality of evidence across a body of evidence was also applied.  </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-05-11 17:29:08 -0700" MODIFIED_BY="[Empty name]">
<P>One randomised trial in 136 patients studied maintaining lamivudine in second-line regimens or not. There was no difference in virological outcomes in the group who maintained lamivudine and those who did not in their subsequent regimens. Two other small observational studies reported in abstract form also did not report a difference in the proportion of those with viral suppression after six months and time to HIV-1 RNA suppression among those on a lamivudine (3TC) or emtricitabine (FTC) regimen compared to those on a 3TC/FTC-sparing second-line regimen. There were no trials identified comparing boosted protease inhibitors (PIs) or nucleoside backbone combinations after first-line failure on non-thymidine analog combinations. Observational studies of populations starting ART in resource-limited settings suggest that short-term response on boosted PI-based regimens is encouraging.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-05-11 16:33:12 -0700" MODIFIED_BY="[Empty name]">
<P>There is limited evidence to evaluate second-line therapies in patients with HIV who fail first-line treatment with a WHO-recommended regimen. One randomised trial in 136 patients and two observational studies (both of low quality) suggest no difference in virological suppression whether or not lamivudine is maintained in a second-line regimen. While outcomes of second-line regimens with boosted PIs are favourable in general, there are no studies comparing boosted PIs directly in populations starting second-line regimens. Current recommendations are based on available resources and patient- and public-health-level considerations.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-05-12 15:18:14 -0700" MODIFIED_BY="Tara Horvath">
<BACKGROUND MODIFIED="2010-05-12 15:15:49 -0700" MODIFIED_BY="Tara Horvath">
<P>Globally, it is estimated there were 33.4 million people living with HIV in 2008, the majority of whom reside in sub-Saharan Africa (<LINK REF="REF-UNAIDS-2009" TYPE="REFERENCE">UNAIDS 2009</LINK>). Highly active antiretroviral therapy (HAART) has markedly reduced the morbidity and mortality of patients with HIV/AIDS (<LINK REF="REF-Palella-1998" TYPE="REFERENCE">Palella 1998</LINK>
<B>; </B>
<LINK REF="REF-Holtgrave-2005" TYPE="REFERENCE">Holtgrave 2005</LINK>). The World Health Organization (WHO)'s current standard initial treatment options include two nucleoside reverse transcriptase inhibitors (NRTIs) and a non-nucleoside reverse transcriptase inhibitor (NNRTI) (<LINK REF="REF-Gilks-2006" TYPE="REFERENCE">Gilks 2006</LINK>).  Significant public and private resources have been devoted over the last five years to rapid scale-up efforts in middle- and low-income countries, where a large proportion of the HIV-infected population resides (<LINK REF="REF-Bendavid-2009" TYPE="REFERENCE">Bendavid 2009</LINK>). A small proportion of patients on ART are on second-line therapy, an estimated 4% of the adults on ART and 1% of children (<LINK REF="REF-Renaud_x002d_Thery-2007" TYPE="REFERENCE">Renaud-Thery 2007</LINK>).  There is increasing recognition of the importance, if not urgency, in prioritising effective and available second-line ART regimens in middle- and low-income countries (<LINK REF="REF-Boyd-2007" TYPE="REFERENCE">Boyd 2007</LINK>; <LINK REF="REF-Gallant-2007" TYPE="REFERENCE">Gallant 2007</LINK>
<B>; </B>
<LINK REF="REF-Sungkanuparph-2007" TYPE="REFERENCE">Sungkanuparph 2007</LINK>). </P>
<P> </P>
<P>
<B>Options for Second-Line Treatment and the Role of Resistance </B>
</P>
<P>Options for second-line therapy after failure on an NNRTI-containing regimen generally involve the switch from the first-line NNRTI to a protease inhibitor (PI) and alternate NRTIs. The WHO recommendations for second-line ART support the use of ideally a minimum of three active drugs with at least one new class of drug; a PI and preferably two new NRTIs are recommended. Protease inhibitors boosted with ritonavir are recommended in second-line treatment as they have a high barrier to genetic resistance and are effective and generally well tolerated. Challenges in selecting the NRTI backbone-component of second-line regimens in low-resource settings include limited access to genotypic resistance testing and limited availability of drug options. In low-resource settings, switching to second-line earlier is associated with access to viral-load monitoring (<LINK REF="REF-Egger-2009" TYPE="REFERENCE">Egger 2009</LINK>) and delayed switching among patients failing a first-line regimen to second-line ART is associated with greater mortality (<LINK REF="REF-Keiser-2009" TYPE="REFERENCE">Keiser 2009</LINK>). In settings in which viral-load monitoring is infrequent and changes to second-line treatment may occur late, there are likely to be accumulations of resistance mutations that compromise second-line regimens. In a recent meta-analysis of resistance mutations after first-line NNRTI-based combination ART, <LINK REF="REF-Gupta-2009" TYPE="REFERENCE">Gupta 2009</LINK> reported that the frequency of lamivudine resistance was 80.5% (95% CI: 72.9-86.8%) in infrequently monitored patients compared to 40.3% (95% CI: 29.1-52.2) in frequently monitored patients (<LINK REF="REF-Gupta-2009" TYPE="REFERENCE">Gupta 2009</LINK>).  Some data suggest a clinical benefit of maintaining lamivudine in a second-line regimen due to diminished "viral fitness" in the presence of the M184V/I mutation (<LINK REF="REF-Campbell-2005" TYPE="REFERENCE">Campbell 2005</LINK>; <LINK REF="REF-Castagna-2006" TYPE="REFERENCE">Castagna 2006</LINK>; <LINK REF="REF-Paredes-2009" TYPE="REFERENCE">Paredes 2009</LINK>). In an open-label, randomised pilot study, patients on lamivudine-containing HAART harbouring M184V mutation were randomised to lamivudine monotherapy or treatment interruption and followed for immunological or clinical failure for 48 weeks; patients on lamivudine monotherapy had delayed clinical or immunological failure compared to those on no drugs (<LINK REF="REF-Castagna-2006" TYPE="REFERENCE">Castagna 2006</LINK>). These potential benefits are balanced by cost, exposure to side effects and drug-drug interactions and antiviral inactivity based on genotypic testing.</P>
<P>The current systematic review is an update to the review of second-line regimens published in 2007 (<LINK REF="REF-Humphreys-2007" TYPE="REFERENCE">Humphreys 2007</LINK>), in which there were no eligible studies identified. Given the proliferation of research on ART and rapid scale-up of ART in low- and middle-income countries, an update was performed. Specific questions about second-line regimens for this review expanded those from the 2007 review to include the following research questions: Which boosted PI should be used in a second-line regimen following failure on an NNRTI-based first-line regimen? Should lamivudine be maintained in second-line regimens? And other questions related to the NRTI backbone. The findings in this review represent, in part, findings of a larger, collaborative effort between the University of California, San Francisco (UCSF); the Centers for Disease Control and Prevention (CDC) and WHO to review evidence of optimum second-line ART regimens that was performed in anticipation of updating the Adult and Adolescent Guidelines for Antiretroviral Therapy (<LINK REF="REF-WHO-2006" TYPE="REFERENCE">WHO 2006</LINK>).</P>
<P>      </P>
<P>
<B>OBJECTIVES</B>
</P>
<CONDITION MODIFIED="2010-05-11 16:57:15 -0700" MODIFIED_BY="[Empty name]">
<P>First-line ART in resource limited settings commonly includes a three-drug combination of an NNRTI plus 2 NRTIs. Due to poor adherence, acquisition of resistant virus or other factors, ART treatment may fail. Treatment failure of ART can be diagnosed clinically, immunologically and by viral-load testing. When failure is diagnosed, ART is switched to include drugs with antiviral activity. It is intended to improve the clinical condition, restore immune function and decrease viral replication.</P>
</CONDITION>
<INTERVENTION MODIFIED="2010-05-11 16:57:28 -0700" MODIFIED_BY="[Empty name]">
<P>The intervention after failure of first-line ART with an NNRTI and two NRTIs involves switching a PI boosted with ritonavir for the NNRTI and using different NRTIs with presumed increased antiviral activity.</P>
</INTERVENTION>
<THEORY MODIFIED="2010-05-11 16:57:38 -0700" MODIFIED_BY="[Empty name]">
<P>Using antiretroviral drugs with activity against the virus will limit viral replication and restore immune function.</P>
</THEORY>
<IMPORTANCE MODIFIED="2010-05-11 16:57:50 -0700" MODIFIED_BY="[Empty name]">
<P>There are many people who have started or who are eligible for ART in low- and middle-income countries. Some of these patients will have treatment failure requiring a second-line ART regimen. Deciding which regimen to use is critical, especially in settings where there are limited drug options.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-05-12 09:40:54 -0700" MODIFIED_BY="[Empty name]">
<P>To assess the optimum second-line ART regimen in adolescents and adults living with HIV failing first-line therapy on NNRTI + two-NRTI regimen in low-resource settings.</P>
</OBJECTIVES>
<METHODS MODIFIED="2010-05-12 15:16:21 -0700" MODIFIED_BY="Tara Horvath">
<SELECTION_CRITERIA MODIFIED="2010-05-12 09:39:30 -0700" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2010-05-11 16:58:27 -0700" MODIFIED_BY="[Empty name]">
<UL>
<LI>Randomised controlled trials (RCTs).</LI>
</UL>
<UL>
<LI>Relevant nonrandomised studies (NRSs) meeting inclusion criteria were also evaluated given the insufficient number of RCTs.</LI>
</UL>
<UL>
<LI>Systematic reviews and meta-analyses addressing interventions of interest were reviewed in detail</LI>
</UL>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-05-11 16:58:37 -0700" MODIFIED_BY="[Empty name]">
<P>Children &#8805;5<B> </B>years of age, adolescents and adults living with HIV failing first-line therapy of a WHO-recommended regimen</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-05-12 09:39:30 -0700" MODIFIED_BY="[Empty name]">
<P>There were a number of second-line interventions of interest, as outlined in the table below. A primary question was which boosted PI to use in the second-line combination ART regimen and whether or not to maintain lamivudine in a three- or four-drug second-line regimen after first-line failure including a thymidine analog regimen.</P>
<P>
<B>Interventions and Comparison (Age &#8805;5)</B>
</P>
<TABLE COLS="2" ROWS="6">
<TR>
<TD>
<P>
<B>Intervention for second-line treatment</B>
</P>
</TD>
<TD>
<P>
<B>Comparator for second-line</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>After failing first-line NNRTI-containing regimen: </I>
</P>
<P>Lopinavir/ritonavir + two-NRTI regimen</P>
</TD>
<TD>
<P>All other boosted PI regimens</P>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>After failing first-line thymidine analog and lamivudine (3TC)-containing regimen: </I>
</P>
<P>NRTI backbone maintaining 3TC (TDF + 3TC or ddI + 3TC)</P>
</TD>
<TD>
<P>NRTI backbone not maintaining 3TC (TDF + ABC or ddI + ABC)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>After failing first-line with abacavir (ABC): </I>
</P>
<P>ZDV + 3TC in NRTI backbone</P>
<P> </P>
</TD>
<TD>
<P>TDF + 3TC or ddI + 3TC in NRTI backbone</P>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>After failing first-line with</I> <I>tenofovir (TDF)-</I>containing regimen (limited to adults since TDF not approved in children):      </P>
<P>ZDV + 3TC in NRTI backbone</P>
</TD>
<TD>
<P>ddI + 3TC in NRTI backbone</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>After failing first-line lamivudine (3TC)-containing regimen: </I>
</P>
<P>Three-drug regimen containing 3TC</P>
<P>
<I> </I>
</P>
</TD>
<TD>
<P>Four-drug regimen maintaining 3TC (e.g., ZDV + TDF + 3TC + lopinavir/r)</P>
<P> </P>
</TD>
</TR>
</TABLE>
<P/>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-05-11 17:16:27 -0700" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2010-05-11 17:14:33 -0700" MODIFIED_BY="[Empty name]">
<P>1)  Mortality</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2010-05-11 17:16:27 -0700" MODIFIED_BY="[Empty name]">
<P>2)  <B>
<U>Severe adverse events.</U>
</B> Severe adverse events were classified according to grade 1 to 4 of the Adverse Event Toxicity Scale (Division of AIDS, National Institutes of Health)<B> </B>and reported as the proportion of participants that experienced grade 3 and 4 clinical and laboratory adverse events. Using this scale, grade 1 and 2 denote mild to moderate symptoms, grade 3 denotes serious symptoms and grade 4 denotes life-threatening events requiring significant clinical intervention.</P>
<P>3)  <B>
<U>Clinical response to ART</U>. </B>We assessed clinical response by the proportion of participants that progressed either to CDC-defined AIDS (i.e. stage III to stage IV disease) or who developed a second opportunistic infection or malignancy. </P>
<P>4)  <B>
<U>Adherence, tolerance, retention</U>. </B>We defined this variable to be the proportion of study participants that reached the end of the study on their initially assigned regimen. This category, therefore, includes participants whose regimens were altered because of toxicity, those lost to follow-up, those whose regimens were changed because of clinical or virologic failure and those who withdrew from the study for other reasons.</P>
<P>5)  <B>
<U>Virologic response to ART</U>. </B>Virologic response was reported as the proportion of participants that reached a predefined concentration of HIV-1 RNA, typically &lt;400 copies/mL, or who suppressed viral replication to nondetectable levels, typically &lt;50 copies/mL. For purposes of meta-analysis we used the lower value.</P>
<P>6)  <B>
<U>Immunologic response to ART</U>. </B>We defined immunologic response to ART as the mean change in the concentration of CD4 lymphocytes from baseline, as expressed in cells/mm<SUP>3</SUP>. When studies presented median, instead of mean, we used the median values as reported.</P>
<P>7)  <B>
<U>Drug Resistance.</U>
</B> Acquisition of major genotypic resistance mutations as reported by authors. Minor mutations were not reported. Reported as a dichotomous outcome as identified by study authors. </P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-05-12 14:58:06 -0700" MODIFIED_BY="Tara Horvath">
<P>We followed standard Cochrane systematic review methodology. We reviewed the search strategy from the prior review, but given broader research questions of interest, we performed a new search.</P>
<ELECTRONIC_SEARCHES MODIFIED="2010-05-12 14:58:06 -0700" MODIFIED_BY="Tara Horvath">
<P>
<U>
<B>Journal and trial databases</B>
</U>
</P>
<UL>
<LI>MEDLINE</LI>
<LI>EMBASE</LI>
<LI>CENTRAL (Cochrane Central Register of Controlled Trials)</LI>
<LI>LILACS (Latin American and Caribbean Health Sciences Literature)</LI>
<LI>Cochrane HIV/AIDS Group Trials Register</LI>
<LI>Web of Science</LI>
</UL>
<P>
<U>
<B>Search Terms</B>
</U>
</P>
<P>Standard HIV/AIDS Cochrane Collaborative Group search terms were used.  Major subject heading terms included: highly active antiretroviral therapy, antiretroviral agents, treatment failure, adherence, resistance, salvage therapy, HIV protease inhibitors and individual drug names. See example of search strategy (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>
<U>Limits</U>
</P>
<P>The searches were performed without limits to language or ages or setting (the searches were not restricted by age as a separate review on second-line regimens in children was performed and reported separately).</P>
<P>The searches were limited to human studies published from 1995 (start of combination antiretroviral therapy era) to July 2009.</P>
<P> </P>
<P>
<B>Inclusion Criteria</B>
</P>
<UL>
<LI>Intervention trial. Given the insufficient number of trials, NRSs (cohort, case control, and case series study designs) were included</LI>
</UL>
<UL>
<LI>Evaluates second-line ART in patients failing first-line, including any three-drug second-line regimens or four-drug regimens that contain lamivudine and include a comparator</LI>
</UL>
<UL>
<LI>Includes a clear definition of failure based on clinical, immunologic and/or virologic criteria and rationale for switching to second-line treatment</LI>
</UL>
<UL>
<LI>Failure of a WHO-recommended first-line regimen, including three-drug regimens of 2 NRTIs + NNRTI</LI>
</UL>
<UL>
<LI>Provides sufficient regimen-specific information about first- and second-line drugs to compare regimens and outcomes of interest</LI>
</UL>
<P> </P>
<P>
<B>Exclusion Criteria</B>
</P>
<UL>
<LI>Studies evaluating ART in patients failing more than one regimen</LI>
</UL>
<UL>
<LI>Letter, editorial, nonsystematic review, case report, cross-sectional study</LI>
</UL>
<UL>
<LI>Studies evaluating substituting rather than switching ART. As described in <LINK REF="REF-WHO-2006" TYPE="REFERENCE">WHO 2006</LINK>, substituting is for toxicities and usually involves single-drug changes while switch is due to clinical, immunologic or virologic failure and involves changing the entire regimen.</LI>
</UL>
<UL>
<LI>Studies evaluating failure of first-line single-drug regimens or four-drug regimens</LI>
</UL>
<UL>
<LI>Studies evaluating second-line four-drug regimens that do not contain lamivudine</LI>
</UL>
<UL>
<LI>Studies evaluating nonboosted PIs in adults</LI>
</UL>
<P> </P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2010-05-12 12:57:51 -0700" MODIFIED_BY="Tara Horvath">
<P>
<U>
<B>Conference databases</B>
</U>
</P>
<UL>
<LI>Aegis: covers abstracts from a number of relevant international conferences including the International AIDS Conference, the International AIDS Society (IAS) Conferences on HIV Pathogenesis, Treatment, and Prevention, the Conference on Retroviruses and Opportunistic Infections (CROI), the British HIV Association Conference and the International Congress on Drug Therapy in HIV infection.</LI>
</UL>
<UL>
<LI>NLM Gateway (for HIV/AIDS conference abstracts before 2005)</LI>
</UL>
<P>We also handsearched conference proceedings from the CROI, International AIDS Conferences and IAS Conferences on HIV Pathogenesis, Treatment, and Prevention from 2005 to 2009.</P>
<P>
<U>
<B>Ongoing trials</B>
</U>
<B>. </B>We searched the following prospective trials registers:</P>
<UL>
<LI>ClinicalTrials.gov (<A HREF="http://clinicaltrials.gov/">http://clinicaltrials.gov/</A>)</LI>
<LI>Current Controlled Trials (<A HREF="http://www.controlled-trials.com/">www.controlled-trials.com/</A>)</LI>
<LI>Pan-African Clinical Trials Registry (<A HREF="http://www.pactr.org">www.pactr.org</A>)</LI>
</UL>
<P>
<U>
<B>Researchers and relevant organizations</B>
</U>
<B>. </B>We contacted individual researchers working in the field, such as the AIDS Clinical Trials Group, and policymakers based in intergovernmental organizations, including the Joint United Nations Programme on HIV/AIDS (UNAIDS) and WHO to identify trials either completed or ongoing.</P>
<P>
<U>
<B>Reference lists</B>
</U>
<B>. </B>We checked the reference lists of all studies identified by the above methods and examine the bibliographies of any systematic reviews, meta-analyses, or current guidelines we identified during the search process.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-05-12 15:16:21 -0700" MODIFIED_BY="Tara Horvath">
<STUDY_SELECTION MODIFIED="2010-05-11 17:20:59 -0700" MODIFIED_BY="[Empty name]">
<P>EH performed an initial screen of all found titles and abstracts, removing all titles which clearly did not fit inclusion criteria or met exclusion criteria (e.g. editorials, letters, clearly off topic studies). Subsequently, two reviewers (LC and EH) independently reviewed all remaining titles. If the title was felt to be relevant by either reviewer, the corresponding abstract was then reviewed by both authors. If either reviewer felt the abstract was potentially relevant, the full text of the article was then reviewed. Disagreements between the two reviewers were adjudicated by a third reviewer (JH).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2010-05-11 17:21:39 -0700" MODIFIED_BY="[Empty name]">
<P>After initial search and article screening, two reviewers (EH and JH) independently double-coded and entered onto a detailed and standardized data extraction form information from selected studies.  Extracted information included:</P>
<P>
<B>Study details:</B> citation, start and end dates, location, study design and details</P>
<P>
<B>Participant details:</B> study population eligibility (inclusion and exclusion) criteria, ages, population size, attrition rate, details of HIV diagnosis and disease and any clinical, immunologic or virologic staging or lab information, first-line drug regimen details including drug name, dose and duration</P>
<P>
<B>Interventions details:</B> second-line drug names, doses, duration, ancillary testing and monitoring, any other information on adherence or resistance. For RCTs, the number randomized and the number analysed for each intervention was recorded.</P>
<P>
<B>Outcome details:</B> mortality, clinical disease progression (AIDS and non-AIDS events), treatment response (CD4 recovery and viral load response), adherence, resistance, and adverse events. For each outcome, the number of participants randomised and the number of participants analysed were recorded for each treatment group. For dichotomous outcomes, we recorded the number experiencing events and the number of patients in each treatment group. For continuous outcomes, we recorded the arithmetic mean and standard deviation and the numbers of patients in each group (if medians are used, we extracted medians and ranges). For count data, we extracted the number of events in the treatment and control group and the total person time at risk in each group or the rate ratio and a measure of variance (standard error, for example) directly from the trial report. If authors only reported adjusted estimates, we abstracted these.</P>
<P>
<U>Nonrandomised studies</U>
</P>
<P>We used the same detailed data extraction sheet for NRSs and collected the relevant information for NRSs described above. For outcomes in NRSs, if studies adjusted for a covariate in the analysis, we recorded the adjusted treatment effect estimate, the estimate, its standard error, and the covariate(s) for which the analysis was adjusted. When the study reported a number of adjusted treatment effects, each result was recorded. If the results were not adjusted for covariates or if both adjusted and unadjusted effects were reported, we extracted the same data as we did for randomised trials.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2010-05-12 09:43:17 -0700" MODIFIED_BY="[Empty name]">
<P>Application of GRADE (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>) and Cochrane Collaboration tools for risk of bias for each individual study were applied and presented in summary tables. The GRADE and Cochrane approaches assess risk of bias in individual studies across six domains: sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other potential biases. </P>
<P>
<I>Sequence generation</I>
<BR/>&#8226; Adequate: investigators described a random component in the sequence generation process, such as the use of random number table, coin tossing, card or envelope shuffling, etc.<BR/>&#8226; Inadequate: investigators described a nonrandom component in the sequence generation process, such as the use of odd or even date of birth, algorithm based on the day or date of birth, hospital, or clinic record number.<BR/>&#8226; Unclear: insufficient information to permit judgement of the sequence generation process.</P>
<P>
<I>Allocation concealment</I>
<BR/>&#8226; Adequate: participants and the investigators enrolling participants cannot foresee assignment (e.g., central allocation; or sequentially numbered, opaque, sealed envelopes).<BR/>&#8226; Inadequate: participants and investigators enrolling participants can foresee upcoming assignment (e.g., an open random allocation schedule, a list of random numbers); or envelopes were unsealed or not opaque or not sequentially numbered.<BR/>&#8226; Unclear: insufficient information to permit judgement of the allocation concealment or the method not described.</P>
<P>
<I>Blinding</I>
<BR/>&#8226; Adequate: blinding of the participants, key study personnel, and outcome assessor, and unlikely that the blinding could have been broken. No blinding in the situation where not blinding is not likely to introduce bias.</P>
<P>&#8226; Inadequate: no blinding or incomplete blinding when the outcome is likely to be influenced by lack of blinding.</P>
<P>&#8226; Unclear: insufficient information to permit judgement of adequacy or otherwise of the blinding.</P>
<P>
<I>Incomplete outcome data</I>
<BR/>&#8226; Adequate: no missing outcome data, reasons for missing outcome data unlikely to be related to true outcome, or missing outcome data balanced in number across groups.<BR/>&#8226; Inadequate: reason for missing outcome data likely to be related to true outcome, with either imbalance in number across groups or reasons for missing data.<BR/>&#8226; Unclear: insufficient reporting of attrition or exclusions.</P>
<P>
<I>Selective reporting</I>
<BR/>&#8226; Adequate: a protocol is available which clearly states the primary outcome as the same as in the final trial report.<BR/>&#8226; Inadequate: the primary outcome differs between the protocol and final trial report.<BR/>&#8226; Unclear: no trial protocol is available or there is insufficient reporting to determine if selective reporting is present.</P>
<P>
<I>Other forms of bias</I>
<BR/>&#8226; Adequate: there is no evidence of bias from other sources.<BR/>&#8226; Inadequate: there is potential bias present from other sources (e.g., early stopping of trial, fraudulent activity, extreme baseline imbalance, or bias related to specific study design).<BR/>&#8226; Unclear: insufficient information to permit judgement of adequacy or otherwise of other forms of bias.</P>
<P>Observational studies were assessed for risk of bias using the Newcastle-Ottawa Quality Assessment Scale (NOS) shown in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> (<LINK REF="REF-Wells-2009" TYPE="REFERENCE">Wells 2009</LINK>). The NOS is a validated scale from 0 to 9 that uses a star rating system and assesses quality of cohort and case-control studies in three main areas: selection of study groups, comparability of study groups and ascertainment of exposure or outcome.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2010-05-11 17:22:52 -0700" MODIFIED_BY="[Empty name]">
<P>Dichotomous outcomes for effect are summarised in terms of risk ratio (RR), risk difference (RD) with their 95% confidence intervals. Continuous outcomes are assessed with a weighted mean difference (WMD) and 95% confidence interval.  In cases where median and range (IQR) were provided, the mean and standard deviation were derived based on methods described by Hozo et al (<LINK REF="REF-Hozo-2005" TYPE="REFERENCE">Hozo 2005</LINK>). Analysis was by intention-to-treat.</P>
<P>RCTs and NRSs were evaluated separately.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2010-05-11 17:23:06 -0700" MODIFIED_BY="[Empty name]">
<P>There were no significant unit of analysis issues identified.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2010-04-15 09:47:25 -0700" MODIFIED_BY="[Empty name]">
<P>Study authors were contacted in cases of incomplete or unreported data. Contact with authors did not result in any data not already published in identified abstracts or manuscripts.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2010-04-15 06:51:22 -0700" MODIFIED_BY="[Empty name]">
<P>Heterogeneity among trials was anticipated using the chi-square statistic with a significance level of 0.10 and the I-squared statistic; however, given that no meta-analysis was performed, these assessments were not performed.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2010-05-11 17:23:28 -0700" MODIFIED_BY="[Empty name]">
<P>Assessment of publication bias planned through funnel plots; however, due to the limited number of studies, these were not contributory.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2010-05-12 13:03:16 -0700" MODIFIED_BY="Tara Horvath">
<P>We used the software for statistical analysis (Review Manager 5) provided by Cochrane Collaboration and GRADEPro (<LINK REF="REF-GRADEpro-2008" TYPE="REFERENCE">GRADEpro 2008</LINK>) software to produce Summary of Findings and GRADE Evidence Profile tables. </P>
<P>Summary statistics using meta-analytic methods were not performed given the limited studies identified and heterogeneity among research questions addressed. Findings are presented in Summary of Findings Tables where appropriate.</P>
<P>
<B>Assessment of Quality of Evidence Across Studies</B>
</P>
<P>The quality of evidence across a body of evidence was assessed with the GRADE approach (see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>), defining the quality of evidence for each outcome as, "the extent to which one can be confident that an estimate of effect or association is close to the quantity of specific interest" (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>).  The quality rating across studies has four levels: high, moderate, low or very low. Randomised trials are categorized as high quality but can be downgraded; similarly, observational studies are categorized as low quality but can be upgraded. Factors that decrease the quality of evidence include limitations in design, indirectness of evidence, unexplained heterogeneity or inconsistency of results, imprecision of results, or high probability of publication bias.  Factors that can increase the quality level of a body of evidence include a large magnitude of effect, if all plausible confounding would reduce a demonstrated effect and if there is a dose-response gradient.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2010-05-11 17:24:24 -0700" MODIFIED_BY="[Empty name]">
<P>Subgroup analysis was planned by ages 15-34 years and 35 years and above and by geographic setting, but the limited findings did not allow for this.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2010-05-12 15:16:21 -0700" MODIFIED_BY="Tara Horvath">
<P>Due to the small number of studies, no sensitivity analysis was performed.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-05-12 15:18:14 -0700" MODIFIED_BY="Tara Horvath">
<STUDY_DESCRIPTION MODIFIED="2010-05-12 09:44:42 -0700" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2010-05-11 17:24:42 -0700" MODIFIED_BY="[Empty name]">
<P>Searches were conducted on July 12, 2009 and produced 1339 titles after duplicates were removed and handsearch results were added.  After initial screening of titles by one reviewer, 229 titles and abstracts were reviewed by two reviewers (LC and EH). EH and LC independently conducted the selection of potentially relevant studies by scanning the titles, abstracts, and descriptor terms of all downloaded material from the electronic searches. Irrelevant reports were discarded, and the full article was obtained for all potentially relevant or uncertain reports. EH and LC independently applied the inclusion criteria. JH acted as arbiter where there was disagreement. Studies were reviewed for relevance, based on study design, types of participants, exposures and outcomes measures.</P>
<P>Fifty-nine abstracts or full articles were reviewed by two authors.  One RCT, one observational study and two abstracts were identified.  See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2010-05-11 17:28:36 -0700" MODIFIED_BY="[Empty name]">
<P>One RCT (<LINK REF="STD-Fox-2006" TYPE="STUDY">Fox 2006</LINK>) and one NRS study<B> (</B>
<LINK REF="STD-Pujades_x002d_Rodriguez-2008" TYPE="STUDY">Pujades-Rodriguez 2008</LINK>) and two conference abstracts (<LINK REF="STD-Murphy-2008" TYPE="STUDY">Murphy 2008</LINK>
<B>; </B>
<LINK REF="STD-Hull-2009" TYPE="STUDY">Hull 2009</LINK>) met inclusion criteria and were extracted. The studies addressed a wide range of second-line questions and were deemed too heterogeneous for pooled estimates. A narrative review was performed.</P>
<P>There were no studies identified evaluating regimens after failure on TDF- or ABC-containing regimens. In addition, there were no studies comparing boosted PIs in second-line regimens.</P>
<P>
<B>Randomised controlled trials</B>
</P>
<P>One RCT (<LINK REF="STD-Fox-2006" TYPE="STUDY">Fox 2006</LINK>) evaluated maintaining lamivudine compared to not maintaining lamivudine in 136 treatment-experienced patients in Europe (COLATE trial). Experienced patients were divided into strata A, those experiencing failure on their first 3TC-containing regimen, and strata B, those experiencing failure on a second or later 3TC-containing regimen. The primary outcome for the open-label, randomised trial was the average area under the curve minus baseline (AAUCMB) reduction in log<SUB>10</SUB> HIV RNA after 48 weeks. Other outcomes included the mean reduction in HIV RNA, median increase from baseline in CD4 T-cell counts, clinical nonfatal adverse events, baseline resistance patterns and evolutionary distances in a subpopulation that had virological sequencing performed.</P>
<P>
<B>Nonrandomised studies</B>
</P>
<P>
<LINK REF="STD-Pujades_x002d_Rodriguez-2008" TYPE="STUDY">Pujades-Rodriguez 2008</LINK> is a descriptive study that evaluated 370 of 48,338 treatment-naive adults who began second-line therapy after initial NNRTI-based first-line regimen in 62 Medecins Sans Frontieres (MSF) centres in 26 resource-limited countries. This observational study evaluated the probability of remaining alive and in care at 12 and 24 months, and factors associated with outcomes on second-line regimens.</P>
<P>
<LINK REF="STD-Murphy-2008" TYPE="STUDY">Murphy 2008</LINK> evaluated second-line LPV/r-based therapy in 189 patients who needed second-line regimens in Durban, South Africa, representing 6% of 3000 patients who initiated ART between July 2004 and February 2007. Seventy-two percent switched due to immunologic and or virologic failure, and the rest due to adverse drug effect or other on NNRTI first-line treatment. The main outcome of the retrospective cohort study was virologic suppression at six months, with evaluation of subgroups including those with ddI in nucleoside backbone or not, one prior regimen or more, and indication for second-line therapy. Adverse events were also documented.</P>
<P>
<LINK REF="STD-Hull-2009" TYPE="STUDY">Hull 2009</LINK> analysed 117 patients in British Columbia, Canada with virologic failure and documented M184V mutation without other NRTI or PI mutations, who were analysed for virologic response on lamivudine (3TC) or emtricitabine (FTC)-containing or -sparing regimens along with boosted PIs and another NRTI. The association between regimens started after identification of M184V mutation and time to HIV-1 RNA suppression was analysed.</P>
<P>Five ongoing trials addressing second-line therapies in low- or middle-income countries were identified (see <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>). </P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2010-05-12 09:44:42 -0700" MODIFIED_BY="[Empty name]">
<P>See <LINK TAG="EXCLUDED_STUDIES_DESCR" TYPE="SECTION">Excluded studies</LINK>.</P>
<P>
<U>
<B>Excluded studies on boosted PIs</B>
</U>
</P>
<P>There are multiple trials comparing boosted PIs in highly treatment-experienced patients or in patients failing first-line PI regimens and started on second-line PI regimens that were outside the scope of this review.  Two RCTs of boosted PI comparisons were identified with mixed populations of ART-experienced and ART-naive patients; the ART-experienced patients were predominantly PI-experienced (<LINK REF="STD-Dragsted-2003" TYPE="STUDY">Dragsted 2003</LINK>
<B>; </B>
<LINK REF="STD-Dragsted-2005" TYPE="STUDY">Dragsted 2005</LINK>).  One additional analysis of different boosted PIs in experienced patients was identified (<LINK REF="STD-de-Mendoza-2006" TYPE="STUDY">de Mendoza 2006</LINK>).  One observational study in Malawi evaluates adults on second-line ART without a comparison group (<LINK REF="STD-Hosseinipour-2009" TYPE="STUDY">Hosseinipour 2009</LINK>).</P>
<P>The MaxCmin1 Trial (<LINK REF="STD-Dragsted-2003" TYPE="STUDY">Dragsted 2003</LINK>) was a randomised, multi-centre, open-label trial comparing indinavir (IDV)/r (800/100 mg) twice daily plus two NRTIs to saquinavir (SQV)/r (1000/100 mg) twice daily plus two NRTIs in 306 patients and was powered to show equivalence between arms (80% chance that 95% confidence interval for the difference in virological failure would exclude a difference &gt;15% in either direction).  Most patients (61%) were PI-experienced and 25% were ART-naive.  At 48 weeks, 27% of patients in the IDV/r and 25% in the SQV/r arm had virological failure.  When switching counted as failure, this difference increased to 49% and 34% between IDV/r and SQV/r, respectively (<I>P</I>=.009).  There was no difference in the time to virologic failure between study arms (P=0.76).  The authors conclude that IDV/r and SQV/r have comparable virologic effects and that there were more treatment-limiting adverse events in the IDV/r arm. </P>
<P>In the MaxCmin2 trial (<LINK REF="STD-Dragsted-2005" TYPE="STUDY">Dragsted 2005</LINK>), the same research group studied lopinavir/ritonavir (400/100 mg) twice daily plus two NRTIs to SQV/r (1000/100 mg) twice daily plus two NRTIs in 324 randomised and exposed (ITT/e) patients, 29% of whom had prior exposure to NNRTIs and 52% of whom had prior PI exposure.  At 48 weeks, 25% of the LPV/r had virologic failure (where discontinuation = failure) compared to 39% in the SQV/r arm (<I>P</I>=.005). Discontinuations occurred in 14% compared to 30% in the LPV/r and SQV/r arms, respectively, and the primary reason for discontinuation was nonfatal adverse events.</P>
<P>In <LINK REF="STD-de-Mendoza-2006" TYPE="STUDY">de Mendoza 2006</LINK>, a retrospective analysis of 389 patients in Spain who had prior PI failure and were given a subsequent boosted PI regimen were evaluated for virologic response and adverse events.  The highest rates of virologic response (VL &lt;50 copies/mL) by ITT analysis occurred in those patients on ATV/r, tipranavir/ritonavir (TPV/r) and LPV/r (72.4%, 68.2% and 54.3% response, respectively).  Discontinuations due to adverse events was highest in the IDV/r group (22.8%) compared to all others (<I>P</I>=.03).  In multivariate analysis, the number of PI mutations at baseline was associated with lower virologic response at week 24 (odds ratio (OR)= 0.77, 95% CI: 0.68-.87; <I>P</I>&lt;.001).</P>
<P>
<LINK REF="STD-Sproat-2005" TYPE="STUDY">Sproat 2005</LINK> compared virologic response of 586 patients in the UK from 1998-2000 who were switched to a regimen containing ddI or non-ddI regimens in the presence or absence of the M184V mutation. Outcomes were factors related to virologic and immunologic success by multivariate analysis.</P>
<P>In <LINK REF="STD-Hosseinipour-2009" TYPE="STUDY">Hosseinipour 2009</LINK>, 101 adults failing first-line ART at two large urban ART clinics in Malawi were started on a second-line regimen of AZT/3TC/TDF/LPV/r and followed for clinical, immunologic and virologic outcomes. The authors performed logistic regression modeling to determine factors associated with mortality and viral suppression. Among survivors at 12 months, 85.2% had HIV RNA &lt;400 copies/mIL with a mean increase in CD4 count of 142 cells/mm<SUP>3</SUP>. Risk factors for death included meeting WHO criteria for clinical failure (OR 3.47, 95% CI: 1.14 to 10.59). Risk factors for death or morbidity included having a baseline CD4 count of &lt;50 cells/mm<SUP>3</SUP>,<SUP> </SUP>a body mass index of &lt;18.5 and a hemoglobin of &lt;10 mg/dL.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-05-12 14:57:41 -0700" MODIFIED_BY="Tara Horvath">
<P>See <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> for NOS for observational studies. See <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> for Assessment of Risk of Bias in included studies.</P>
<ALLOCATION MODIFIED="2009-12-16 09:32:11 -0800" MODIFIED_BY="[Empty name]">
<P>The trial addressing 3TC use in second-line therapy (<LINK REF="STD-Fox-2006" TYPE="STUDY">Fox 2006</LINK>) had adequate sequence generation, and allocation concealment.  </P>
</ALLOCATION>
<BLINDING MODIFIED="2009-12-15 13:27:06 -0800" MODIFIED_BY="[Empty name]">
<P>Fox was not a blinded trial. </P>
</BLINDING>
<EXCLUSIONS MODIFIED="2009-12-16 09:32:24 -0800" MODIFIED_BY="[Empty name]">
<P>For <LINK REF="STD-Fox-2006" TYPE="STUDY">Fox 2006</LINK>, outcome reporting for the primary efficacy data was complete.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2009-12-16 09:32:32 -0800" MODIFIED_BY="[Empty name]">
<P>There does not appear to be selective reporting from <LINK REF="STD-Fox-2006" TYPE="STUDY">Fox 2006</LINK>.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2010-05-12 08:15:34 -0700" MODIFIED_BY="[Empty name]">
<P>The Fox study was supported by industry in the early phases, although there is a low likelihood of bias since the study findings do not supprt an industry-sponsored drug.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-05-12 15:18:14 -0700" MODIFIED_BY="Tara Horvath">
<P>The COLATE trial (<LINK REF="STD-Fox-2006" TYPE="STUDY">Fox 2006</LINK>) found no significant difference in AAUCMB reduction in log<SUB>10</SUB> HIV RNA copies/mL in patients who maintained 3TC in their second-line regimen compared to those who did not. The mean number of antiretroviral drugs other than 3TC received was 3.5 (3.2-3.8) for the On-3TC arm and 3.4 (3.1-3.7) in the Off-3TC arm.  The results did not differ by experience with ART; in strata A (those experiencing failure on their first 3TC-containing regimen) for the On-3TC group, the mean reduction in HIV RNA log<SUB>10</SUB> copies/mL was 1 (95% CI: 0.7-1.4) and in the Off-3TC group it was 1.4 (95% CI: 1-1.8) log<SUB>10</SUB> copies/mL, while for strata B (those experiencing failure on a second or later 3TC-containing regimen), it was 1.6 (95% CI: 1.3-1.9) log<SUB>10</SUB> copies/mL in the On-3TC group compared to 1.5 (95% CI: 1.3-1.8) log<SUB>10 </SUB>copies/mL in the Off-3TC group (<I>P</I>=0.75). There was a difference in mean reduction in log<SUB>10</SUB> HIV RNA from baseline between strata; for those on their second regimen (strata A), the mean reduction from baseline was 1.2 (95% CI: 0.9-1.5) log<SUB>10 </SUB>copies/mL and for those with more ART experience (strata B), the reduction was 1.6 (95% CI: 1.4-1.8, <I>P</I>=0.02) log<SUB>10 </SUB>copies/mL. There were insignificant differences in time to virological failure, CD4 count, time to viral suppression between those maintaining 3TC and those not maintaining 3TC (data not shown).  The overall proportion of patients achieving HIV RNA &lt;50 copies/mL by week 48 increased to 59% in the On-3TC arm and 46% in the Off-3TC arm from baseline (0%) by week 48 (<I>P</I>=0.17). See <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK> and <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>.</P>
<P>These findings are illustrated in <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>. A GRADE Evidence Profile of this comparison can be found on the following Cochrane HIV/AIDS Group web site: <A HREF="http://www.igh.org/Cochrane/GRADE">http://www.igh.org/Cochrane/GRADE</A>.</P>
<P>The <LINK REF="STD-Hull-2009" TYPE="STUDY">Hull 2009</LINK>
<B> </B>abstract also suggests similar time to virologic response among patients with M184V mutation and no PI mutations or other NRTI mutations who subsequently took 3TC or FTC plus NRTI plus a boosted PI (reference) compared to those on a 3TC- or FTC-sparing NRTI regimen plus boosted PI (HR 0.61, 95% CI: 0.37-1.03) or those on 3TC or FTC plus NRTI plus boosted PI plus other active agents (HR 1.09, 95% CI: 0.60-1.96). </P>
<P>
<LINK REF="STD-Murphy-2008" TYPE="STUDY">Murphy 2008</LINK> reports in an abstract no difference in viral suppression at six months among 76 patients with an NRTI backbone including ddI (AZT/ddI) on LPV/r-based second-line compared to 79 without a ddI backbone (AZT/3TC or d4T/3TC or other) in South Africa. Overall, 82% of patients analysed achieved viral suppression at six months.</P>
<P>
<LINK REF="STD-Pujades_x002d_Rodriguez-2008" TYPE="STUDY">Pujades-Rodriguez 2008</LINK> did not report a difference in one compared to two new NRTI drugs in a second-line regimen on incidence of death or loss to follow-up in patients evaluated in multiple MSF centres. </P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-05-12 13:05:47 -0700" MODIFIED_BY="Tara Horvath">
<SUMMARY_OF_RESULTS MODIFIED="2010-05-12 08:43:03 -0700" MODIFIED_BY="[Empty name]">
<P>The current review aimed to address a number of questions related to use of NRTIs and boosted PIs in second-line therapy. Similar to the first review of second-line therapy, after first-line NNRTI-based regimen failure, on which the current review is based, despite a comprehensive search, very few studies of relevance were identified.  One randomised trial of 136 adults suggests no difference in virological outcomes among those maintaining 3TC on second-line regimens with three or four drugs compared to those who do not.  Observational study abstracts support this finding (<LINK REF="STD-Murphy-2008" TYPE="STUDY">Murphy 2008</LINK>; <LINK REF="STD-Hull-2009" TYPE="STUDY">Hull 2009</LINK>). The present review had expanded research questions from the 2007 review to include whether or not 3TC should be maintained in a second-line regimen. Consequently, the <LINK REF="STD-Fox-2006" TYPE="STUDY">Fox 2006</LINK> study is included here yet was not included in the prior review.</P>
<P>No direct comparisons of boosted PIs in second-line treatment after first-line failure in an NNRTI-based regimen were identified. In general, observational studies in adults in low-resource settings suggest a promising response to second-line therapies with boosted PIs (<LINK REF="STD-Murphy-2008" TYPE="STUDY">Murphy 2008</LINK>; <LINK REF="STD-Pujades_x002d_Rodriguez-2008" TYPE="STUDY">Pujades-Rodriguez 2008</LINK>; <LINK REF="STD-Hosseinipour-2009" TYPE="STUDY">Hosseinipour 2009</LINK>).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2010-05-12 09:48:30 -0700" MODIFIED_BY="[Empty name]">
<P>Large trials comparing sequencing of NRTI backbone components of ART regimens are not available, and, while there are trials ongoing of second-line regimens that will offer insight in the future, choices of the NRTI backbone will likely continue to rely on tested or presumed resistance pattern mutations and availability of drugs. The question of whether to maintain lamivudine in second-line regimens despite widespread presence of M184V/I mutation is addressed in this review, in which there was no difference in outcomes in patients who continued the drug compared to those who did not from one RCT and support from two other NRS abstracts. There are however, important limitations in the applicability of this evidence. In the Fox trial, most patients were on four drugs with access to genotype testing and close follow-up. In addition, patients did well in regard to viral suppression, so differences between regimens may not have been apparent in these small population sizes. Evidence from other studies is not entirely consistent. In heavily treatment-experienced patients on at least three-drug combination ART, maintaining inactive NRTIs was not associated with improved virologic outcomes (<LINK REF="REF-Trottier-2009" TYPE="REFERENCE">Trottier 2009</LINK>). However, earlier reports have suggested some clinical benefit or partial viral suppression with lamivudine use despite the presence of M184V mutations (<LINK REF="REF-Campbell-2005" TYPE="REFERENCE">Campbell 2005</LINK>; <LINK REF="REF-Castagna-2006" TYPE="REFERENCE">Castagna 2006</LINK>). The M184V mutation has been shown to reduce replicative capacity of the virus in vitro and also to render the virus less fit in vivo compared to wild-type virus (<LINK REF="REF-Wainberg-1996" TYPE="REFERENCE">Wainberg 1996</LINK>; <LINK REF="REF-Devereux-2001" TYPE="REFERENCE">Devereux 2001</LINK>; <LINK REF="REF-Paredes-2009" TYPE="REFERENCE">Paredes 2009</LINK>). Using inactive NRTIs is akin to a functional monotherapy, making recent studies of PI monotherapy potentially relevant. A 2009 systematic review, however, reported that the risk of therapy failure was greater on monotherapy in the six LPV/r monotherapy trials included (<LINK REF="REF-Bierman-2009" TYPE="REFERENCE">Bierman 2009</LINK>). Ongoing work in this area and the results from second-line ART trials in RLS evaluting boosted PI monotherapy are eagerly anticipated (see <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>).</P>
<P>While there was limited data identified in patients failing first-line NNRTI + two-NRTI regimens going on to second-line boosted PI regimens, the evidence of boosted PI comparisons in treatment-naive populations may provide insight for the treatment experienced, PI-naive population. Several recent randomised trials comparing lopinavir/ritonavir in combination to fosamprenavir/ritonavir, atazanavir/ritonavir and darunvavir/ritonavir in combination with two NRTIs have shown the studied boosted PI tob be not inferior to lopinavir/ritonavir for primary outcomes of viral suppression at 48 weeks (<LINK REF="REF-Eron-2006" TYPE="REFERENCE">Eron 2006</LINK>; <LINK REF="REF-Molina-2008" TYPE="REFERENCE">Molina 2008</LINK>; <LINK REF="REF-Ortiz-2008" TYPE="REFERENCE">Ortiz 2008</LINK>). Darunavir has been shown to be superior at 96 weeks to lopinavir, with fewer side effects (<LINK REF="REF-Mills-2009" TYPE="REFERENCE">Mills 2009</LINK>) in treatment-naive patients. A recent review summarizes the major trials (<LINK REF="REF-Llibre-2009" TYPE="REFERENCE">Llibre 2009</LINK>).</P>
<P>The present review was intended to provide evidence to guide second-line treatment recommendations for patients failing a WHO-recommended first-line regimen. Studies evaluating patients on salvage therapy or those on regimens other than NNRTI + two-NRTI first-line regimens were excluded based on the assumption of varying resistance patterns and lack of generalizability to most patient populations in resource-limited settings. Many study populations have had prior exposure to more than one regimen, limiting study findings. Indirect evidence from patients on salvage regimens or treatment-naive patients (in the setting of bPI comparisons) may be important evidence that was not evaluated comprehensively in the current review.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2010-05-12 13:05:47 -0700" MODIFIED_BY="Tara Horvath">
<P>There is a low quality of evidence addressing the question of maintaining lamivudine in second-line from one RCT and two observational studies. The quality of evidence is downgraded for imprecision (few events) and from indirectness (see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). There is indirect evidence that FPV/r, ATV/r and DRV/r are not inferior to LPV/r in combination ART in treatment-naive patients at 48 weeks.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2010-05-12 13:03:53 -0700" MODIFIED_BY="Tara Horvath">
<P>Biases in the review process were minimised by not limiting the search by language and by performing a comprehensive search of databases and conference proceedings and by contacting experts. Nevertheless, judgements regarding assessment of bias, GRADE quality of evidence assessments and study inclusion criteria are inevitable. Efforts to minimise these potential biases were made throughout the review process and, where judgments were required, decisions are transparent.</P>
</POTENTIAL_BIASES>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-05-12 09:40:08 -0700" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2010-05-12 09:40:08 -0700" MODIFIED_BY="[Empty name]">
<P>There is insufficient direct evidence to evaluate second-line therapies in patients failing first-line regimens with NNRTI + two NRTIs. Current clinical practice for treatment of patients with HIV who fail first-line treatment is based on indivualised treatment decisions based on resistance testing and clinician choice and/or the availability and affordability of second-line regimens.</P>
<P>The WHO has issued an update to the 2006 recommendations for ART in adults and adolescents (<LINK REF="REF-WHO-2006" TYPE="REFERENCE">WHO 2006</LINK>; <LINK REF="REF-WHO-2009" TYPE="REFERENCE">WHO 2009</LINK>, <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>).</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-05-12 08:56:36 -0700" MODIFIED_BY="[Empty name]">
<P>Urgent trials are needed to guide second-line therapy in low- and middle-income countries. Ongoing trials identified in this review will contribute substantially to the next generation of recommendations for second-line ART.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-04-28 09:57:44 -0700" MODIFIED_BY="[Empty name]">
<P>We gratefully acknowledge the contributions of Nancy Santesso and Holger Schunemann for their consultation and technical expertise with GRADEPro and Grade Evidence Profile presented in this review. We would also like to thank Tara Horvath at the Cochrane Group on HIV/AIDS at UCSF and Joy Oliver at the South African Cochrane Centre for their assistance with searches, and Andrew Anglemeyer for his consultation on statistical matters. We would like to thank Alicen Spaulding, Gail Kennedy, George Rutherford and Nandi Siegfried for their collaboration and support.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2009-12-15 08:12:43 -0800" MODIFIED_BY="[Empty name]">
<P>None.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-05-12 09:02:28 -0700" MODIFIED_BY="[Empty name]">
<P>All authors contributed to the design and conduct of this study as well as with manuscript drafting and submission.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-05-12 13:01:33 -0700" MODIFIED_BY="Tara Horvath">
<STUDIES MODIFIED="2010-05-04 15:54:01 -0700" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2010-04-16 11:40:25 -0700" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Fox-2006" MODIFIED="2009-12-15 13:43:59 -0800" MODIFIED_BY="[Empty name]" NAME="Fox 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-12-15 13:43:59 -0800" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fox Z, Dragsted UB, Gerstoft J, Phillips AN, Kjaer J, Mathiesen L, et al</AU>
<TI>A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial</TI>
<SO>Antiviral therapy</SO>
<YR>2006</YR>
<VL>11</VL>
<NO>6</NO>
<PG>761-70</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="17310820"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hull-2009" MODIFIED="2009-12-16 09:29:09 -0800" MODIFIED_BY="[Empty name]" NAME="Hull 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-12-16 09:29:09 -0800" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hull M, Moore D, et al. A lamivudine (3TC)-based backbone in conjunction with a boosted protease inhibitor (PI) is sufficient to achieve virologic suppression in the presence of M184V mutations. Program and abstracts of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2009; San Francisco, CA. Abstract H-916</AU>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-12-16 09:27:42 -0800" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murphy-2008" MODIFIED="2010-04-16 11:40:25 -0700" MODIFIED_BY="[Empty name]" NAME="Murphy 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-04-16 11:40:25 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Murphy RA, Sunpath H, et al</AU>
<TO>Lopinavir/ritonavir (LPV/r) + 2 nucleoside analogues as second-line ART in Protease-inhibitor naive adults in South Africa: Outcomes and Adverse Effects</TO>
<SO>15th Conference on Retroviruses and Opportunistic Infections</SO>
<YR>February 3-6, 2008. Poster Abstract No. 831</YR>
<CY>Boston, MA</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pujades_x002d_Rodriguez-2008" MODIFIED="2009-12-10 12:16:09 -0800" MODIFIED_BY="[Empty name]" NAME="Pujades-Rodriguez 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-12-10 12:16:09 -0800" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pujades-Rodriguez M, O'Brien D, Humblet P, Calmy A</AU>
<TI>Second-line antiretroviral therapy in resource-limited settings: the experience of Medecins Sans Frontieres</TI>
<SO>AIDS (London, England)</SO>
<YR>2008</YR>
<VL>22</VL>
<NO>11</NO>
<PG>1305-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="18580610"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-05-04 15:54:01 -0700" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-de-Mendoza-2006" MODIFIED="2009-12-16 07:17:00 -0800" MODIFIED_BY="[Empty name]" NAME="de Mendoza 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-12-16 07:17:00 -0800" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Mendoza C, Valer L, Ribera E, Barreiro P, Martin-Carbonero L, Ramirez G, et al</AU>
<TI>Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients</TI>
<SO>HIV clinical trials</SO>
<YR>2006</YR>
<VL>7</VL>
<NO>4</NO>
<PG>163-71</PG>
<IDENTIFIERS MODIFIED="2009-12-16 07:16:58 -0800" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="17065028"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dragsted-2003" MODIFIED="2009-12-16 07:17:00 -0800" MODIFIED_BY="[Empty name]" NAME="Dragsted 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-12-16 07:17:00 -0800" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dragsted UB, Gerstoft J, Pedersen C, Peters B, Duran A, Obel N, et al</AU>
<TI>Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial</TI>
<SO>The Journal of infectious diseases</SO>
<YR>2003</YR>
<VL>188</VL>
<NO>5</NO>
<PG>635-42</PG>
<IDENTIFIERS MODIFIED="2009-12-16 07:16:58 -0800" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="12934178"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dragsted-2005" MODIFIED="2009-12-16 07:17:00 -0800" MODIFIED_BY="[Empty name]" NAME="Dragsted 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-12-16 07:17:00 -0800" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dragsted UB, Gerstoft J, Youle M, Fox Z, Losso M, Benetucci J, et al</AU>
<TI>A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial</TI>
<SO>Antiviral therapy</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>6</NO>
<PG>735-43</PG>
<IDENTIFIERS MODIFIED="2009-12-16 07:16:58 -0800" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="16218173"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gomo-2008" MODIFIED="2010-01-12 08:04:56 -0800" MODIFIED_BY="[Empty name]" NAME="Gomo 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-01-12 08:04:14 -0800" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gomo Z, Walker S, Hakim J, et al</AU>
<TI>Impact of lopinavir/ritonavir (Kaltera) based second-line antiretroviral therapy regimen on lipid and lipoprotein profiles in an African setting</TI>
<SO>XVII International AIDS Conference; August 3-8, 2008. Mexico City, Mexico</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-01-12 07:59:06 -0800" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hosseinipour-2009" MODIFIED="2010-05-04 15:54:01 -0700" MODIFIED_BY="[Empty name]" NAME="Hosseinipour 2009" YEAR="2010">
<REFERENCE MODIFIED="2010-05-04 15:54:01 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hosseinipour MC, Kumwenda JJ, Weigel R, Brown LB, Mzinganjira D, Mhango B, et al</AU>
<TI>Clinical, Immunological, and Virological Outcomes of Second-line Treatment, Malawi</TI>
<SO>16th Conference on Retroviruses and Opportunistic Infections</SO>
<YR>February 8-11, 2009</YR>
<PG>Paper # 605</PG>
<CY>Montreal, CA</CY>
<IDENTIFIERS MODIFIED="2010-05-04 15:54:01 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-05-04 15:54:01 -0700" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sproat-2005" MODIFIED="2009-12-16 07:17:00 -0800" MODIFIED_BY="[Empty name]" NAME="Sproat 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-12-16 07:17:00 -0800" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sproat M, Pozniak AL, Peeters M, Winters B, Hoetelmans R, Graham NM, et al</AU>
<TI>The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine</TI>
<SO>Antiviral therapy</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>2</NO>
<PG>357-61</PG>
<IDENTIFIERS MODIFIED="2009-12-16 07:16:58 -0800" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="15865231"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-12-17 18:03:46 -0800" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2010-01-14 09:11:11 -0800" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-ANRS12169" MODIFIED="2010-01-14 07:22:10 -0800" MODIFIED_BY="[Empty name]" NAME="ANRS12169" YEAR="">
<REFERENCE MODIFIED="2010-01-14 07:18:16 -0800" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<TI>Multicentric, Non-Inferiority, Randomized, Non-Blinded Phase 3 Trial Comparing Virological Response at 48 Weeks of 3 Antiretroviral Treatment Regimens in HIV-1-Infected Patients With Treatment Failure After 1st Antiretroviral Therapy (Cameroon, Burkina Faso, Senegal)</TI>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-01-14 07:10:14 -0800" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-14 07:10:14 -0800" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00928187"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-EARNEST" MODIFIED="2010-01-14 09:11:11 -0800" MODIFIED_BY="[Empty name]" NAME="EARNEST" YEAR="">
<REFERENCE MODIFIED="2010-01-14 08:29:41 -0800" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<TI>A Randomised Controlled Trial to Evaluate Options for Second-line Therapy in Patients Failing a First-line 2NRTI + NNRTI Regimen in Africa</TI>
<IDENTIFIERS MODIFIED="2010-01-14 08:29:41 -0800" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-01-14 09:11:11 -0800" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-14 09:11:11 -0800" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00988039"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HIV-NAT" MODIFIED="2010-01-14 07:16:10 -0800" MODIFIED_BY="[Empty name]" NAME="HIV NAT" YEAR="">
<REFERENCE MODIFIED="2010-01-14 07:16:06 -0800" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<TI>The HIV Second-Line Therapy Antiretroviral Study in Patients Who Failed NNRTI-Based Regimens</TI>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-01-14 07:12:59 -0800" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-14 07:12:59 -0800" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00627055"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00931463" MODIFIED="2010-01-14 07:44:20 -0800" MODIFIED_BY="[Empty name]" NAME="NCT00931463" YEAR="">
<REFERENCE MODIFIED="2010-01-14 07:19:04 -0800" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<TI>A Randomised Open-Label Study Comparing the Safety and Efficacy of Ritonavir Boosted Lopinavir and 2-3 N(t)RTI Backbone Versus Ritonavir Boosted Lopinavir and Raltegravir in Participants Virologically Failing First-Line NNRTI+2N(t)RTI Therapy</TI>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-01-14 07:04:39 -0800" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-14 07:04:39 -0800" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00931463"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SARA-_x0028_ISRTCN53817258_x0029_" MODIFIED="2010-01-14 08:36:36 -0800" MODIFIED_BY="[Empty name]" NAME="SARA (ISRTCN53817258)" YEAR="">
<REFERENCE MODIFIED="2010-01-14 08:31:00 -0800" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<TI>Second-line Anti-Retroviral therapy in Africa: a randomised trial to evaluate the feasibility of maintenance monotherapy with ritonavir-boosted lopinavir (Aluvia® tablets) following initiation with 24 weeks of combination therapy in second-line anti-retroviral therapy in Africa</TI>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-01-14 08:13:28 -0800" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-14 08:13:28 -0800" MODIFIED_BY="[Empty name]" TYPE="ISRCTN" VALUE="53817258"/>
</IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-05-12 13:01:33 -0700" MODIFIED_BY="Tara Horvath">
<ADDITIONAL_REFERENCES MODIFIED="2010-05-12 13:01:33 -0700" MODIFIED_BY="Tara Horvath">
<REFERENCE ID="REF-Bendavid-2009" MODIFIED="2009-07-09 13:33:25 -0700" MODIFIED_BY="[Empty name]" NAME="Bendavid 2009" TYPE="JOURNAL_ARTICLE">
<AU>Bendavid E, Wood R, Katzenstein DA, Bayoumi AM, Owens DK</AU>
<TI>Expanding Antiretroviral Options in Resource-Limited Settings-A Cost-Effectiveness Analysis</TI>
<SO>Journal of acquired immune deficiency syndromes (1999)</SO>
<YR>2009</YR>
<IDENTIFIERS MODIFIED="2009-07-09 13:33:23 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="19448557"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bierman-2009" MODIFIED="2010-01-12 07:42:47 -0800" MODIFIED_BY="[Empty name]" NAME="Bierman 2009" TYPE="OTHER">
<AU>Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, Boucher CA</AU>
<TI>HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review</TI>
<SO>AIDS (London, England)</SO>
<YR>2009</YR>
<VL>23</VL>
<NO>3</NO>
<PG>279-91</PG>
<IDENTIFIERS MODIFIED="2010-01-12 07:42:45 -0800" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="19114854"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Boyd-2007" MODIFIED="2009-07-09 13:35:09 -0700" MODIFIED_BY="[Empty name]" NAME="Boyd 2007" TYPE="JOURNAL_ARTICLE">
<AU>Boyd MA, Cooper DA</AU>
<TI>Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research</TI>
<SO>AIDS (London, England)</SO>
<YR>2007</YR>
<VL>21 Suppl 4</VL>
<PG>S55-63</PG>
<IDENTIFIERS MODIFIED="2009-07-09 13:35:06 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="17620754"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Campbell-2005" MODIFIED="2010-01-08 10:51:53 -0800" MODIFIED_BY="[Empty name]" NAME="Campbell 2005" TYPE="JOURNAL_ARTICLE">
<AU>Campbell TB, Shulman NS, Johnson SC, Zolopa AR, Young RK, Bushman L, et al</AU>
<TI>Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection</TI>
<SO>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</SO>
<YR>2005</YR>
<VL>41</VL>
<NO>2</NO>
<PG>236-42</PG>
<IDENTIFIERS MODIFIED="2010-01-08 10:51:51 -0800" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="15983922"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Castagna-2006" MODIFIED="2010-01-08 10:51:53 -0800" MODIFIED_BY="[Empty name]" NAME="Castagna 2006" TYPE="JOURNAL_ARTICLE">
<AU>Castagna A, Danise A, Menzo S, Galli L, Gianotti N, Carini E, et al</AU>
<TI>Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study)</TI>
<SO>AIDS (London, England)</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>6</NO>
<PG>795-803</PG>
<IDENTIFIERS MODIFIED="2010-01-08 10:51:51 -0800" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="16549962"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Devereux-2001" MODIFIED="2010-01-14 10:33:00 -0800" MODIFIED_BY="[Empty name]" NAME="Devereux 2001" TYPE="JOURNAL_ARTICLE">
<AU>Devereux HL, Emery VC, Johnson MA, Loveday C</AU>
<TI>Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations</TI>
<SO>Journal of medical virology</SO>
<YR>2001</YR>
<VL>65</VL>
<NO>2</NO>
<PG>218-24</PG>
<IDENTIFIERS MODIFIED="2010-01-14 10:32:58 -0800" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="11536226"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Egger-2009" MODIFIED="2009-07-09 13:33:25 -0700" MODIFIED_BY="[Empty name]" NAME="Egger 2009" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Keiser O</AU>
<TI>Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring</TI>
<SO>AIDS (London, England)</SO>
<YR>2009</YR>
<IDENTIFIERS MODIFIED="2009-07-09 13:33:23 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="19531928"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Eron-2006" MODIFIED="2010-01-12 07:42:47 -0800" MODIFIED_BY="[Empty name]" NAME="Eron 2006" TYPE="JOURNAL_ARTICLE">
<AU>Eron J Jr, Yeni P, Gathe J Jr, Estrada V, DeJesus E, Staszewski S, et al</AU>
<TI>The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial</TI>
<SO>Lancet</SO>
<YR>2006</YR>
<VL>368</VL>
<NO>9534</NO>
<PG>476-82</PG>
<IDENTIFIERS MODIFIED="2010-01-12 07:42:45 -0800" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="16890834"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gallant-2007" MODIFIED="2009-12-15 13:43:51 -0800" MODIFIED_BY="[Empty name]" NAME="Gallant 2007" TYPE="OTHER">
<AU>Gallant JE</AU>
<TI>Drug resistance after failure of initial antiretroviral therapy in resource-limited countries</TI>
<SO>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</SO>
<YR>2007</YR>
<VL>44</VL>
<NO>3</NO>
<PG>453-5</PG>
<IDENTIFIERS MODIFIED="2009-12-15 13:43:49 -0800" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="17205458"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gilks-2006" MODIFIED="2009-12-15 13:43:51 -0800" MODIFIED_BY="[Empty name]" NAME="Gilks 2006" TYPE="JOURNAL_ARTICLE">
<AU>Gilks CF, Crowley S, Ekpini R, Gove S, Perriens J, Souteyrand Y, et al</AU>
<TI>The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings</TI>
<SO>Lancet</SO>
<YR>2006</YR>
<VL>368</VL>
<NO>9534</NO>
<PG>505-10</PG>
<IDENTIFIERS MODIFIED="2009-12-15 13:43:49 -0800" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="16890837"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro-2008" MODIFIED="2010-05-12 13:01:33 -0700" MODIFIED_BY="Tara Horvath" NAME="GRADEpro 2008" TYPE="COMPUTER_PROGRAM">
<AU>Jan Brozek, Andrew Oxman, Holger Schunemann</AU>
<TI>Version 3.2 for Windows.</TI>
<YR>2008</YR>
<PB>GRADE Working Group</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gupta-2009" MODIFIED="2009-12-15 13:43:51 -0800" MODIFIED_BY="[Empty name]" NAME="Gupta 2009" TYPE="JOURNAL_ARTICLE">
<AU>Gupta RK, Hill A, Sawyer AW, Cozzi-Lepri A, von Wyl V, Yerly S, et al</AU>
<TI>Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis</TI>
<SO>The Lancet infectious diseases</SO>
<YR>2009</YR>
<VL>9</VL>
<NO>7</NO>
<PG>409-17</PG>
<IDENTIFIERS MODIFIED="2009-12-15 13:43:49 -0800" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="19555900"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2008" MODIFIED="2010-04-27 12:10:27 -0700" MODIFIED_BY="[Empty name]" NAME="Guyatt 2008" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al</AU>
<TI>GRADE: an emerging consensus on rating quality of evidence and strength of recommendations</TI>
<SO>BMJ (Clinical research ed.)</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7650</NO>
<PG>924-6 [PubMed: 18436948]</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2009-12-16 09:16:48 -0800" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="BOOK">
<AU>Higgins JPT, Green S (editors)</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions.</SO>
<YR>2008</YR>
<PB>John Wiley &amp; Sons Ltd</PB>
<CY>Chichester</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Holtgrave-2005" MODIFIED="2009-12-15 13:43:51 -0800" MODIFIED_BY="[Empty name]" NAME="Holtgrave 2005" TYPE="JOURNAL_ARTICLE">
<AU>Holtgrave DR</AU>
<TI>Causes of the decline in AIDS deaths, United States, 1995-2002: prevention, treatment or both?</TI>
<SO>International journal of STD &amp; AIDS</SO>
<YR>2005</YR>
<VL>16</VL>
<NO>12</NO>
<PG>777-81</PG>
<IDENTIFIERS MODIFIED="2009-12-15 13:43:49 -0800" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="16336756"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hozo-2005" MODIFIED="2010-01-21 10:09:15 -0800" MODIFIED_BY="[Empty name]" NAME="Hozo 2005" TYPE="JOURNAL_ARTICLE">
<AU>Hozo SP, Djulbegovic B, Hozo I</AU>
<TI>Estimating the mean and variance from the median, range, and the size of a sample</TI>
<SO>BMC medical research methodology</SO>
<YR>2005</YR>
<VL>5</VL>
<NO>1</NO>
<PG>13</PG>
<IDENTIFIERS MODIFIED="2010-01-21 10:09:13 -0800" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="15840177"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Humphreys-2007" MODIFIED="2009-12-15 13:43:51 -0800" MODIFIED_BY="[Empty name]" NAME="Humphreys 2007" TYPE="JOURNAL_ARTICLE">
<AU>Humphreys EH, Hernandez LB, Rutherford GW</AU>
<TI>Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy</TI>
<SO>Cochrane database of systematic reviews (Online)</SO>
<YR>2007</YR>
<NO>4</NO>
<PG>CD006517</PG>
<IDENTIFIERS MODIFIED="2009-12-15 13:43:49 -0800" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="17943914"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Keiser-2009" MODIFIED="2010-01-14 11:32:23 -0800" MODIFIED_BY="[Empty name]" NAME="Keiser 2009" TYPE="JOURNAL_ARTICLE">
<AU>Keiser O, Tweya H, Braitstein P, Dabis F, Macphail P, Boulle A, et al</AU>
<TI>Mortality after failure of antiretroviral therapy in sub-Saharan Africa</TI>
<SO>Tropical medicine &amp; international health : TM &amp; IH</SO>
<YR>2009</YR>
<IDENTIFIERS MODIFIED="2010-01-14 11:32:21 -0800" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="20003034"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Llibre-2009" MODIFIED="2010-01-12 07:42:47 -0800" MODIFIED_BY="[Empty name]" NAME="Llibre 2009" TYPE="JOURNAL_ARTICLE">
<AU>Llibre JM</AU>
<TI>First-line boosted protease inhibitor-based regimens in treatment-naive HIV-1-infected patients--making a good thing better</TI>
<SO>AIDS reviews</SO>
<YR>2009</YR>
<VL>11</VL>
<NO>4</NO>
<PG>215-22</PG>
<IDENTIFIERS MODIFIED="2010-01-12 07:42:45 -0800" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="19940948"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mills-2009" MODIFIED="2010-01-12 07:42:47 -0800" MODIFIED_BY="[Empty name]" NAME="Mills 2009" TYPE="JOURNAL_ARTICLE">
<AU>Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard PM, et al</AU>
<TI>Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis</TI>
<SO>AIDS (London, England)</SO>
<YR>2009</YR>
<VL>23</VL>
<NO>13</NO>
<PG>1679-88</PG>
<IDENTIFIERS MODIFIED="2010-01-12 07:42:45 -0800" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="19487905"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Molina-2008" MODIFIED="2010-01-12 07:42:47 -0800" MODIFIED_BY="[Empty name]" NAME="Molina 2008" TYPE="JOURNAL_ARTICLE">
<AU>Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, et al</AU>
<TI>Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study</TI>
<SO>Lancet</SO>
<YR>2008</YR>
<VL>372</VL>
<NO>9639</NO>
<PG>646-55</PG>
<IDENTIFIERS MODIFIED="2010-01-12 07:42:45 -0800" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="18722869"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ortiz-2008" MODIFIED="2010-01-12 07:42:47 -0800" MODIFIED_BY="[Empty name]" NAME="Ortiz 2008" TYPE="JOURNAL_ARTICLE">
<AU>Ortiz R, Dejesus E, Khanlou H, Voronin E, van Lunzen J, Andrade-Villanueva J, et al</AU>
<TI>Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48</TI>
<SO>AIDS (London, England)</SO>
<YR>2008</YR>
<VL>22</VL>
<NO>12</NO>
<PG>1389-97</PG>
<IDENTIFIERS MODIFIED="2010-01-12 07:42:45 -0800" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="18614861"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Palella-1998" MODIFIED="2009-12-15 13:43:51 -0800" MODIFIED_BY="[Empty name]" NAME="Palella 1998" TYPE="JOURNAL_ARTICLE">
<AU>Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al</AU>
<TI>Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators</TI>
<SO>The New England journal of medicine</SO>
<YR>1998</YR>
<VL>338</VL>
<NO>13</NO>
<PG>853-60</PG>
<IDENTIFIERS MODIFIED="2009-12-15 13:43:49 -0800" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="9516219"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Paredes-2009" MODIFIED="2010-01-08 10:51:53 -0800" MODIFIED_BY="[Empty name]" NAME="Paredes 2009" TYPE="JOURNAL_ARTICLE">
<AU>Paredes R, Sagar M, Marconi VC, Hoh R, Martin JN, Parkin NT, et al</AU>
<TI>In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine</TI>
<SO>Journal of virology</SO>
<YR>2009</YR>
<VL>83</VL>
<NO>4</NO>
<PG>2038-43</PG>
<IDENTIFIERS MODIFIED="2010-01-08 10:51:51 -0800" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="19019971"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Renaud_x002d_Thery-2007" MODIFIED="2009-12-15 13:43:51 -0800" MODIFIED_BY="[Empty name]" NAME="Renaud-Thery 2007" TYPE="JOURNAL_ARTICLE">
<AU>Renaud-Thery F, Nguimfack BD, Vitoria M, Lee E, Graaff P, Samb B, et al</AU>
<TI>Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens</TI>
<SO>AIDS (London, England)</SO>
<YR>2007</YR>
<VL>21 Suppl 4</VL>
<PG>S89-95</PG>
<IDENTIFIERS MODIFIED="2009-12-15 13:43:49 -0800" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="17620758"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sungkanuparph-2007" MODIFIED="2009-07-09 13:33:25 -0700" MODIFIED_BY="[Empty name]" NAME="Sungkanuparph 2007" TYPE="JOURNAL_ARTICLE">
<AU>Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W</AU>
<TI>Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails</TI>
<SO>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</SO>
<YR>2007</YR>
<VL>44</VL>
<NO>3</NO>
<PG>447-52</PG>
<IDENTIFIERS MODIFIED="2009-07-09 13:33:23 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="17205457"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Trottier-2009" MODIFIED="2010-01-14 09:44:47 -0800" MODIFIED_BY="[Empty name]" NAME="Trottier 2009" TYPE="CONFERENCE_PROC">
<AU>Trottier B, Thomas R, Nguyen V-K, et al</AU>
<TI>Should inactive nucleoside/tide reverse transcriptase inhibitors (NRTIs) still be used in salvage regimens, with new classes/generations of antiretrovirals in three-class-experienced, multi-drug resistant patients?</TI>
<SO>5th IAS Conference on HIV Pathogenesis, Treatment and Prevention</SO>
<YR>July 19-22, 2009</YR>
<PG>Abtract No. TUPDB205</PG>
<CY>Cape Town, South Africa</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-UNAIDS-2009" MODIFIED="2010-04-16 11:41:22 -0700" MODIFIED_BY="[Empty name]" NAME="UNAIDS 2009" TYPE="OTHER">
<AU>UNAIDS2009 Report on global AIDS epidemic. Available online at: http://data.unaids.org/pub/Report/2009/2009_epidemic_update_en.pdf. Accessed December 15, 2009</AU>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wainberg-1996" MODIFIED="2010-01-14 10:33:00 -0800" MODIFIED_BY="[Empty name]" NAME="Wainberg 1996" TYPE="JOURNAL_ARTICLE">
<AU>Wainberg MA, Drosopoulos WC, Salomon H, Hsu M, Borkow G, Parniak M, et al</AU>
<TI>Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase</TI>
<SO>Science (New York, N.Y.)</SO>
<YR>1996</YR>
<VL>271</VL>
<NO>5253</NO>
<PG>1282-5</PG>
<IDENTIFIERS MODIFIED="2010-01-14 10:32:58 -0800" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="8638110"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wells-2009" MODIFIED="2010-04-23 14:03:53 -0700" MODIFIED_BY="[Empty name]" NAME="Wells 2009" TYPE="OTHER">
<AU>Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P</AU>
<TO>The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses</TO>
<SO>Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm Accessed 22 June 2009</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2006" MODIFIED="2010-04-15 08:47:51 -0700" MODIFIED_BY="[Empty name]" NAME="WHO 2006" TYPE="BOOK">
<SO>Guidelines for Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a public health approach</SO>
<YR>2006</YR>
<PB>World Health Organization</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2009" MODIFIED="2010-04-16 11:41:51 -0700" MODIFIED_BY="[Empty name]" NAME="WHO 2009" TYPE="BOOK">
<AU>World Health Organization</AU>
<SO>Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents</SO>
<YR>November 2009. Available at: http://www.who.int/hiv/pub/arv/rapid_advice_art.pdf</YR>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-05-12 09:49:19 -0700" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-05-12 09:49:19 -0700" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-05-12 09:03:43 -0700" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fox-2006">
<CHAR_METHODS MODIFIED="2010-04-28 09:11:44 -0700" MODIFIED_BY="[Empty name]">
<P>Open-label randomised controlled trial in 12 European countries during June 1999 to May 2002.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 09:03:17 -0700" MODIFIED_BY="[Empty name]">
<P>136 adults with virological failure randomised and 131 intitiated assigned treatment, which was to maintain lamivudine in clinician-chosen follow-up regimen (On-3TC, n=65) or not (Off-3TC, n=66). Two a priori subgroups analysed based on prior regimen exposure (strata A, 1 prior regimen with 3TC n=55; and strata B, more than one prior regimen with 3TC n=76).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-04-27 12:09:43 -0700" MODIFIED_BY="[Empty name]">
<P>Regimen maintaining 3TC (On-3TC) or not (Off-3TC). Remainder of regimen chosen by clinician.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 09:03:43 -0700" MODIFIED_BY="[Empty name]">
<P>1. Average area under the curve minus baseline of mean reduction in log<SUB>10</SUB> HIV RNA copies/mL after 48 weeks</P>
<P>2. Mean log<SUB>10</SUB> HIV RNA reductions</P>
<P>3. Clinical nonfatal adverse events</P>
<P>4. Nucleotide distances substudy looking at evolutionary distances and number of nucleotide changes that occured from baseline sequences.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 14:00:47 -0800" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-04-16 11:30:43 -0700" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hull-2009">
<CHAR_METHODS MODIFIED="2009-12-15 13:55:52 -0800" MODIFIED_BY="[Empty name]">
<P>Retrospective cohort</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-16 11:30:43 -0700" MODIFIED_BY="[Empty name]">
<P>184 patients with documented M184V mutations and subsequently began a boosted PI regimen. 117 patients were resistant to 3TC with or without NNRTI mutations (no PI-mutations or other NRTI mutations) followed at British Columbia HIV Drug Treatment Center 2000-2006</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 13:55:30 -0800" MODIFIED_BY="[Empty name]">
<P>Regimen A: 3TC or FTC + NRTI + bPI</P>
<P>Regimen B: 3TC or FTC + NRTI + bPI + additional active agent(s)</P>
<P>Regimen C: 2 NRTIs + bPI +/- additional active agents (sparing 3TC or FTC)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-19 11:00:23 -0800" MODIFIED_BY="[Empty name]">
<P>1. Time to HIV-1 RNA suppression </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-19 11:02:55 -0800" MODIFIED_BY="[Empty name]">
<P>Analysis is on 117 patients with M184V</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 09:49:19 -0700" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Murphy-2008">
<CHAR_METHODS MODIFIED="2010-01-14 09:58:05 -0800" MODIFIED_BY="[Empty name]">
<P>Retrospective cohort</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 09:48:37 -0700" MODIFIED_BY="[Empty name]">
<P>184 patients requiring second-line regimen in Durban, South Africa among 3,000 starting ART between the years 2004-2007. First-line for majority was d4T/3TC/EFZ.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 09:49:19 -0700" MODIFIED_BY="[Empty name]">
<P>LPV/r based second-line ART</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 09:05:46 -0700" MODIFIED_BY="[Empty name]">
<P>1. primary outcome virologic suppression at six months with evaluation of subgroups based on: 1) NRTI backbone (ddI containing vs not); 2) One prior regimen or more than one prior regimen; 3) indication for second-line regimen (failure vs adverse drug effect/other).</P>
<P>2. adverse effects</P>
<P>3. lipid outcomes</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-16 11:31:46 -0700" MODIFIED_BY="[Empty name]">
<P>Abstract, limited information and no apparent adjusting in analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 09:06:50 -0700" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pujades_x002d_Rodriguez-2008">
<CHAR_METHODS MODIFIED="2009-12-17 18:29:46 -0800" MODIFIED_BY="[Empty name]">
<P>Descriptive analysis using individual patient data from 62 MSF-supported HIV centres in 26 countries between 2001 and 2006.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 09:04:50 -0700" MODIFIED_BY="[Empty name]">
<P>370 (0.8%) out of 48,338 patients on second-line regimen after NNRTI first-line; &gt;15 years of age.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 09:06:32 -0700" MODIFIED_BY="[Empty name]">
<P>51% on LPV-based second-line regimen, 43% on NFV-based second-line; 56% on boosted PI. ZDV-ddI (34%) and ABC-ddI (22%) most common backbone in second-line treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 09:06:50 -0700" MODIFIED_BY="[Empty name]">
<P>1. Probability of remaining on first-line ART</P>
<P>2. Rate of switch to second-line ART</P>
<P>3. Probablilities of remaining alive and in care at 12 and 24 months after first- and second-line therapy initiation</P>
<P>4. Comparison of probabilities of remaining alive and in care in patients started on second-line or not (among patients on ART for more than 19.8 months)</P>
<P>5. Description of patient characteristics at start of ART and switch</P>
<P>6. Factors associated with death and loss to follow-up.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-05-12 09:29:52 -0700" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2010-01-12 07:03:33 -0800" MODIFIED_BY="[Empty name]" STUDY_ID="STD-de-Mendoza-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-12 07:03:33 -0800" MODIFIED_BY="[Empty name]">
<P>Observational study of 389 PI-experienced patients comparing performance of six different boosted PI-based regimens. PIs are not components of WHO-recommended first-line ART.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-16 11:32:21 -0700" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dragsted-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-16 11:32:21 -0700" MODIFIED_BY="[Empty name]">
<P>Randomized, open-label, multicentre, Phase IV trial comparing SQV/r to IDV/r based regimens in 306 patients, most of whom were PI-experienced (61%). Trial was not powered to detect differences in outcomes based on PI-experience, nor are outcomes reported by PI-experience. PIs are not components of WHO-recommended first-line ART.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-12 09:26:59 -0700" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dragsted-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-12 09:26:59 -0700" MODIFIED_BY="[Empty name]">
<P>Randomized, open-label, multicentre, Phase IV trial comparing LPV/r to SQV/r-based regimens in 324 treatment-naive and treatment-experienced patients, 52% of whom were PI-experienced. Authors did not differentiate results among ART-naïve and experienced patients, nor among experienced patients who had previously used PIs. PIs are not components of WHO-recommended first-line ART.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-01-12 07:05:24 -0800" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gomo-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-12 07:05:24 -0800" MODIFIED_BY="[Empty name]">
<P>An analysis of 91 patients from the DART trial who switched to second-line therapy and were evaluated for changes in lipid profiles.  All patients had LPV/r-based second-line therapy (regimens included LPV/r +NNRTI or LPV/r + NNRTI + ddI or LPV/r +TDF + ddI/3TC/AZT) after triple nucleoside first-line therapy (in 91%). Lipid profiles were not an outcome we considered.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-12 09:27:22 -0700" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hosseinipour-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-12 09:27:22 -0700" MODIFIED_BY="[Empty name]">
<P>Evaluation of adults in two large urban ART clinics in Malawi with clinical failure on first-line ART. Second-line ART with AZT/3TC/TDF/LPV/r was started in 101 participants who were followed for clinical and immunological and virological outcomes. There is no comparison group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-12 09:29:52 -0700" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sproat-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-12 09:29:52 -0700" MODIFIED_BY="[Empty name]">
<P>Observational study comparing virologic response of 586 patients in the UK from 1998-2000 who were switched to ddI- or non-ddI-containing regimens in the presence or absence of the M184V mutation. Outcomes were factors related to virologic and immunologic success by multivariate analysis. Regimen-specific details regarding first- and second-line ART not provided.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-12-17 18:03:46 -0800" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2010-05-12 09:47:41 -0700" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2010-05-12 09:47:41 -0700" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ANRS12169">
<CHAR_STUDY_NAME MODIFIED="2010-01-14 07:35:02 -0800" MODIFIED_BY="[Empty name]">
<P>Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé) (2LADY)<BR/>
</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-01-14 07:23:09 -0800" MODIFIED_BY="[Empty name]">
<P>Randomized, open-label, active control, parallel assignment, efficacy study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 09:31:02 -0700" MODIFIED_BY="[Empty name]">
<P>450 patients over the age of 18 years meeting the following criteria:</P>
<UL>
<LI>Documented HIV-1 infection regardless of clinical stage and CD4 lymphocyte count</LI>
</UL>
<UL>
<LI>Patient with treatment failure after first-line antiretroviral treatment with a combination including a NNRTI and two NRTIs, failure being defined as two measurements (at 1 month intervals) of plasma HIV RNA levels &gt;1000 copies/mL after at least six months of uninterrupted treatment</LI>
</UL>
<UL>
<LI>Adherence (&gt;80%) to first- line ART (questionnaire) at pre-inclusion</LI>
</UL>
<UL>
<LI>Patient agrees not to take any concomitant medication during the trial without informing the investigator</LI>
</UL>
<UL>
<LI>For women in childbearing age: negative pregnancy test at inclusion, with no plan of pregnancy in the coming 12 months and agreeing to use mechanical contraception (with or without hormonal contraception) during the study</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 09:47:06 -0700" MODIFIED_BY="[Empty name]">
<P>Arm A:</P>
<P>emtricitabine/tenofovir + lopinavir/ritonavir<BR/>Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + Lopinavir 200 mg/Ritonavir 50 mg two tablets in the morning and two tablets in the evening</P>
<P>
<BR/>Arm B:<BR/>abacavir + didanosine + lopinavir/ritonavir<BR/>Didanosine 1 entero-coated capsule/day in fasting conditions (dosage 250 mg if weight &lt;60 kg, 400 mg if weight &gt;60 kg) + abacavir 300 mg 1 tablet in the morning and in the evening + Lopinavir 200 mg/Ritonavir 50 mg two tablets morning and evening</P>
<P>
<BR/>Arm C:<BR/>emtricitabine/tenofovir + darunavir + ritonavir<BR/>Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + darunavir 400 mg 2 tablets + ritonavir 100 mg 1 capsule, in a single dose with food</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 09:47:41 -0700" MODIFIED_BY="[Empty name]">
<P>Primary outcome:</P>
<UL>
<LI>Proportion of patients with plasma HIV RNA &lt;50 copies/mL at 48 weeks.</LI>
</UL>
<P>Secondary outcomes:</P>
<UL>
<LI>Clinical outcome (AIDS events, non-AIDS events, death, undesirable effects) at 48 weeks</LI>
</UL>
<UL>
<LI>Proportion of patients with plasma HIV RNA &lt;200 and 50 copies/mL at 24 weeks ]</LI>
</UL>
<UL>
<LI>Proportion of patients with plasma HIV RNA &lt;200 copies/mL at 48 weeks</LI>
</UL>
<UL>
<LI>Variation of circulating CD4+ lymphocyte count at 24, 48 weeks</LI>
</UL>
<UL>
<LI>Treatment discontinuation at 24, 48 weeks</LI>
</UL>
<UL>
<LI>Tolerance, particularly the occurrence of hypersensitivity syndromes, renal impairment, and changes in lipids profile, gastrointestinal complains and lipodystrophy at 24, 48 weeks</LI>
</UL>
<UL>
<LI>Changes in anthropometric measures at 24, 48 weeks</LI>
</UL>
<UL>
<LI>Adherence (measured by pill count and questionnaire) at 24, 48 weeks</LI>
</UL>
<UL>
<LI>Frequency of resistance mutations after second-line treatment failure (HIV RNA &gt;1000 copies/mL) at 24, 48 weeks</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2010-01-14 07:27:48 -0800" MODIFIED_BY="[Empty name]">
<P>November 2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2010-01-14 07:29:21 -0800" MODIFIED_BY="[Empty name]"/>
<CHAR_NOTES MODIFIED="2010-01-14 07:35:35 -0800" MODIFIED_BY="[Empty name]">
<P>Burkina Faso, Cameroon, Senegal</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-05-12 09:45:44 -0700" MODIFIED_BY="[Empty name]" STUDY_ID="STD-EARNEST">
<CHAR_STUDY_NAME MODIFIED="2010-01-14 08:34:19 -0800" MODIFIED_BY="[Empty name]">
<P>Europe-Africa Research Network for Evaluation of Second-line Therapy (EARNEST) </P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-01-14 08:21:33 -0800" MODIFIED_BY="[Empty name]">
<P>Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 09:45:44 -0700" MODIFIED_BY="[Empty name]">
<P>1200 patients with the following inclusion criteriaL:</P>
<UL>
<LI>Previously documented HIV infection on at least one standard antibody-based test</LI>
</UL>
<UL>
<LI>Age 12 years and above</LI>
</UL>
<UL>
<LI>Taking two-NRTI + NNRTI-based regimen continuously for at least 12 months</LI>
</UL>
<UL>
<LI>Naive to PI therapy</LI>
</UL>
<UL>
<LI>Good adherence to ART in the 12 weeks prior to screening defined as no more than 10% of doses missed</LI>
</UL>
<UL>
<LI>Clinically stable and receiving treatment for any known opportunistic infections</LI>
</UL>
<UL>
<LI>HIV treatment failure defined by one or more of clinical, immunological or virological criteria defined in the protocol, including VL and CD4 at screening visit</LI>
</UL>
<UL>
<LI>Willing and able to give informed consent</LI>
</UL>
<UL>
<LI>Able to attend for regular study follow-up visits</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 09:33:24 -0700" MODIFIED_BY="[Empty name]">
<P>Arm I: lopinavir/ritonavir 400mg/100mg twice daily plus two NRTIs (The choice of NRTIs will be at the discretion of the managing clinician and based on the local standard of care and drug availability, taking into account patient's previous drug exposure and side effects on first-line therapy)</P>
<P>Arm II: lopinavir/ritonavir 400mg/100mg twice daily plus<BR/>raltegravir (400mg) twice daily</P>
<P>Arm III: lopinavir/ritonavir 400mg/100mg twice daily plus<BR/>raltegravir (400mg) twice daily for the first 12 weeks only</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 09:33:53 -0700" MODIFIED_BY="[Empty name]">
<P>Primary Outcome Measures:</P>
<UL>
<LI>Good HIV disease control defined as a composite endpoint consisting of all of: - No new WHO stage 4 events - CD4 count &gt;250 cells/mm<SUP>3</SUP> - viral load &lt;10,000 copies/mL or &gt;10,000 copies/mL with no PI resistance mutations at week 96</LI>
</UL>
<P>Secondary Outcome Measures:</P>
<UL>
<LI>Good HIV disease control</LI>
</UL>
<UL>
<LI>Proportion with CD4 cell count &gt;250 cells/mm<SUP>3</SUP> at 96 and 144 weeks</LI>
</UL>
<UL>
<LI>Proportion with new or recurrent WHO stage 4 event at 96 and 144 weeks</LI>
</UL>
<UL>
<LI>Proportion of patients with plasma viral load &lt;50 copies at week 48, week 96 and week 144</LI>
</UL>
<UL>
<LI>Adverse events</LI>
</UL>
<UL>
<LI>Quality of life change from randomisation</LI>
</UL>
<UL>
<LI>Neurocognitive function change from randomisation</LI>
</UL>
<UL>
<LI>Healthcare costs</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2010-01-14 08:23:07 -0800" MODIFIED_BY="[Empty name]">
<P>October 2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES MODIFIED="2010-01-14 08:32:15 -0800" MODIFIED_BY="[Empty name]">
<P>Malawi, Uganda, Zimbabwe</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-05-12 09:41:17 -0700" MODIFIED_BY="[Empty name]" STUDY_ID="STD-HIV-NAT">
<CHAR_STUDY_NAME MODIFIED="2010-01-14 07:50:02 -0800" MODIFIED_BY="[Empty name]">
<P>Second-Line Therapy Antiretroviral in Patients Who Failed Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) - Based Regimens</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-01-14 07:50:22 -0800" MODIFIED_BY="[Empty name]">
<P>Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 09:34:26 -0700" MODIFIED_BY="[Empty name]">
<P>200 patients who meet the following inclusion criteria:</P>
<UL>
<LI>Age &#8805;18 years</LI>
</UL>
<UL>
<LI>HIV seropositive</LI>
</UL>
<UL>
<LI>Have had NNRTI-based HAART in the past for at least six months</LI>
</UL>
<UL>
<LI>Naïve to PIs</LI>
</UL>
<UL>
<LI>Plasma HIV RNA &#8805;1000 copies/mL</LI>
</UL>
<UL>
<LI>Signed written informed consent</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 09:41:17 -0700" MODIFIED_BY="[Empty name]">
<P>Arm I:<BR/>LPV/r 400mg/100mg orally q12h for 48 weeks</P>
<P>
<BR/>Arm II:<BR/>LPV/r + two NRTIs (TDF/FTC or TDF/3TC)<BR/>TDF/FTC (Truvada) 1 pill orally q 24 hr or TDF 300mg orally q 24 hr/3TC 300mg orally q 24 hr (or 3TC 150mg orally q 12 hr) for 48 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 09:34:40 -0700" MODIFIED_BY="[Empty name]">
<P>Primary Outcome Measures:<BR/>To evaluate the 48-week efficacy and safety between 2 NRTIs plus lopinavir/ritonavir (LPV/r) and LPV/r monotherapy in patients failing a standard NNRTI-based treatment regimen at 48 weeks<BR/>
<BR/>Secondary Outcome Measures:<BR/>1. To evaluate the short-term 24-week efficacy and safety of LPV/r monotherapy and interim analyses when 50% of the patients in each arm have reached 24 weeks after randomisation</P>
<P>2. To define risk factors for monotherapy failure in HIV-treated individuals at 48 weeks</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2010-01-14 07:53:40 -0800" MODIFIED_BY="[Empty name]">
<P>May 2008</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES MODIFIED="2010-01-14 07:54:22 -0800" MODIFIED_BY="[Empty name]">
<P>Thailand</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-05-12 09:36:08 -0700" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00931463">
<CHAR_STUDY_NAME MODIFIED="2010-01-14 07:36:50 -0800" MODIFIED_BY="[Empty name]">
<P>A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen (SECOND-LINE)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-01-14 07:41:14 -0800" MODIFIED_BY="[Empty name]">
<P>Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 09:35:43 -0700" MODIFIED_BY="[Empty name]">
<P>550 patients who meet the following inclusion criteria:</P>
<UL>
<LI>HIV-1 positive by licensed diagnostic test</LI>
</UL>
<UL>
<LI>Aged 16 years or older (or minimum age as determined by local regulations or as legal requirements dictate)</LI>
</UL>
<UL>
<LI>Have received first antiretroviral regimen consisting of an NNRTI plus two N(t)RTIs for at least 24 weeks</LI>
</UL>
<UL>
<LI>No change in ART within 12 weeks prior to screening</LI>
</UL>
<UL>
<LI>Failed first-line NNRTI plus two N(t)RTI combination therapy according to virological criteria defined by two consecutive (at least 7 days apart) HIV RNA results of greater then 500 copies/mL</LI>
</UL>
<UL>
<LI>No prior or current exposure to HIV PIs and/or HIV integrase inhibitors</LI>
</UL>
<UL>
<LI>Able to provide written informed consent</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 09:35:51 -0700" MODIFIED_BY="[Empty name]">
<P>Arm I. ritonavir-boosted lopinavir (LPV/r) 200mg/50mg 4 tabs once daily or 2 tabs twice daily + 2-3N(t)RTIs</P>
<P>
<BR/>Arm II. ritonavir-boosted lopinavir (LPV/r) 200mg/50mg 4 tabs once daily or 2 tabs twice daily + raltegravir 400 mg twice daily</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 09:36:08 -0700" MODIFIED_BY="[Empty name]">
<P>Primary outcome measure: the proportion of participants with HIV RNA &lt;200 copies/mL 48 weeks after randomisation<BR/>
<BR/>Secondary Outcome Measures:<BR/>virological, immunological, safety and ART endpoints at 48 weeks</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2010-01-14 07:37:55 -0800" MODIFIED_BY="[Empty name]">
<P>September 2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES MODIFIED="2010-01-14 07:43:46 -0800" MODIFIED_BY="[Empty name]">
<P>48 Study Locations</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-05-12 09:36:57 -0700" MODIFIED_BY="[Empty name]" STUDY_ID="STD-SARA-_x0028_ISRTCN53817258_x0029_">
<CHAR_STUDY_NAME MODIFIED="2010-01-14 08:18:19 -0800" MODIFIED_BY="[Empty name]">
<P>Second-line Anti-Retroviral therapy in Africa: a randomised trial to evaluate the feasibility of maintenance monotherapy with ritonavir-boosted lopinavir (Aluvia® tablets) following initiation with 24 weeks of combination therapy in second-line anti-retroviral therapy in Africa (SARA)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-01-14 08:15:01 -0800" MODIFIED_BY="[Empty name]">
<P>Three-centre open-label randomised pilot trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 09:36:46 -0700" MODIFIED_BY="[Empty name]">
<P>240 patients with the following inclusion criteria:</P>
<P>1. Enrolled in the DART trial (http://www.controlled-trials.com/ISRCTN13968779)<BR/>2. Failed first-line ART (clinically/immunologically) and having completed 24 weeks of second-line combination ART including ritonavir-boosted lopinavir (as either Aluvia® heat-stable tablets or Kaletra® capsules)<BR/>3. Documented informed consent<BR/>4. Life expectancy of at least three months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 09:36:57 -0700" MODIFIED_BY="[Empty name]">
<P>Arm 1: Continued combination Aluvia-containing ART</P>
<P>
<BR/>Arm 2: Maintenance with Aluvia monotherapy<BR/>
<BR/>The dose of Aluvia is two tablets twice a day (each tablet is 200 mg of lopinavir with 50 mg of ritonavir) for both arms. All drugs are taken orally</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-14 08:14:24 -0800" MODIFIED_BY="[Empty name]">
<P>Primary outcomes:</P>
<P>1. Change in CD4 count at 24 weeks after randomisation (efficacy)<BR/>2. Any Serious Adverse Event (SAE), which is not HIV related only (safety)</P>
<P>Secondary outcomes:</P>
<P>1. Progression to a new or recurrent WHO stage 4 HIV event or death<BR/>2. Progression to a new or recurrent WHO stage 3 or 4 HIV event or death<BR/>3. Change in CD4 count from SARA randomisation to 48, 72 and 96 weeks<BR/>4. Any grade 3 or 4 adverse events<BR/>5. HIV RNA viral load (performed retrospectively) at 12, 24, 36, 48, 72 and 96 weeks<BR/>6. Adherence as measured by questionnaire and pill counts<BR/>7. Health economic outcomes</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2010-01-14 08:16:45 -0800" MODIFIED_BY="[Empty name]">
<P>July 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES MODIFIED="2010-01-14 08:16:52 -0800" MODIFIED_BY="[Empty name]">
<P>Uganda, Zimbabwe</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-04-16 11:30:03 -0700" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-04-16 11:29:47 -0700" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-16 11:29:47 -0700" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fox-2006">
<DESCRIPTION>
<P>Computerized block randomization performed at CHIP</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-17 18:04:09 -0800" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hull-2009">
<DESCRIPTION>
<P>see NOS scale</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-17 18:04:39 -0800" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Murphy-2008">
<DESCRIPTION>
<P>see NOS scale</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-17 18:04:50 -0800" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pujades_x002d_Rodriguez-2008">
<DESCRIPTION>
<P>see NOS scale</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-04-16 11:29:59 -0700" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-16 11:29:59 -0700" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fox-2006">
<DESCRIPTION>
<P>Per communication with author, allocation by central fax</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-17 18:04:16 -0800" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hull-2009">
<DESCRIPTION>
<P>see NOS scale</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-17 18:04:40 -0800" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Murphy-2008">
<DESCRIPTION>
<P>see NOS scale</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-17 18:04:52 -0800" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pujades_x002d_Rodriguez-2008">
<DESCRIPTION>
<P>see NOS scale</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-12-17 18:04:54 -0800" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-15 14:04:52 -0800" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fox-2006">
<DESCRIPTION>
<P>Open-label study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-17 18:04:20 -0800" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hull-2009">
<DESCRIPTION>
<P>see NOS scale</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-17 18:04:42 -0800" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Murphy-2008">
<DESCRIPTION>
<P>see NOS scale</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-17 18:04:54 -0800" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pujades_x002d_Rodriguez-2008">
<DESCRIPTION>
<P>see NOS scale</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-04-16 11:30:03 -0700" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-04-16 11:30:03 -0700" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fox-2006">
<DESCRIPTION>
<P>For primary outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-17 18:04:23 -0800" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hull-2009">
<DESCRIPTION>
<P>see NOS scale</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-17 18:04:43 -0800" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Murphy-2008">
<DESCRIPTION>
<P>see NOS scale</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-17 18:04:55 -0800" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pujades_x002d_Rodriguez-2008">
<DESCRIPTION>
<P>see NOS scale</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2009-12-17 18:04:57 -0800" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 14:05:20 -0800" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fox-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-17 18:04:26 -0800" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hull-2009">
<DESCRIPTION>
<P>see NOS scale</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-17 18:04:45 -0800" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Murphy-2008">
<DESCRIPTION>
<P>see NOS scale</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-17 18:04:57 -0800" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pujades_x002d_Rodriguez-2008">
<DESCRIPTION>
<P>see NOS scale</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2009-12-17 18:04:59 -0800" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 14:04:41 -0800" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fox-2006">
<DESCRIPTION>
<P>Supported by Glaxo Wellcome in early phases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-17 18:04:29 -0800" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hull-2009">
<DESCRIPTION>
<P>see NOS scale</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-17 18:04:47 -0800" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Murphy-2008">
<DESCRIPTION>
<P>see NOS scale</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-17 18:04:59 -0800" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pujades_x002d_Rodriguez-2008">
<DESCRIPTION>
<P>see NOS scale</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2010-05-06 12:40:30 -0700" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2010-05-06 12:40:30 -0700" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2010-05-06 12:40:28 -0700" MODIFIED_BY="Grade Profiler">Lamivudine in second-line therapy</TITLE>
<TABLE COLS="7" ROWS="8">
<TR>
<TD COLSPAN="7">
<P>
<B>Lamivudine in second-line therapy</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with first-line ART failure<BR/>
<B>Settings:</B> Resource limited settings<BR/>
<B>Intervention:</B> Lamivudine<BR/>
<B>Comparison: </B>No lamivudine</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>No lamivudine</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Lamivudine</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mortality</B> - not measured</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>One death in Off-3TC arm reported from Table 1 </P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Disease progression</B> - not measured</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Severe adverse events</B>
<BR/>Follow-up: 48 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>131<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No difference in adverse events between arms; 43/94 (45.7%) in On-3TC arm and 51/94 (54.3%) in Off-3TC arm (p=0.25)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adherence/tolerability/retention</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Proportion achieving VL &lt;50 copies/ml</B>
<BR/>Follow-up: 48 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>455 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>587 per 1000</B>
<BR/>(419 to 819)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.29 </B>
<BR/>(0.92 to 1.8)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>131<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Change from baseline in CD4</B>
<BR/>Follow-up: 48 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean change from baseline in cd4 in the control groups was<BR/>
<B>77 cells/mm3</B>
<SUP>5</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean Change from baseline in CD4 in the intervention groups was<BR/>
<B>11 higher</B>
<BR/>(10.09 lower to 32.09 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>131<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect. <BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Numbers reported are non-fatal clinical adverse events per arm/total adverse events (which occurred among 49 participants). Further information not reported. <BR/>
<SUP>2</SUP> Open-label study; not downgraded for this. Partial funding from Industry in early phases of trial; also not downgraded for this (low risk of bias since study drug not favoured significantly by results).<BR/>
<SUP>3</SUP> Clinician-optimized regimen; patients not from low-resource settings (study population from European countries).<BR/>
<SUP>4</SUP> Few events <BR/>
<SUP>5</SUP> Mean change from baseline CD4 count estimated from median and IQR using methods described in Hozo 2005</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2010-05-12 14:57:41 -0700" MODIFIED_BY="Tara Horvath">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2010-05-12 14:57:41 -0700" MODIFIED_BY="Tara Horvath" NO="1">
<TITLE MODIFIED="2010-05-12 14:56:34 -0700" MODIFIED_BY="Tara Horvath">Example of search strategies</TITLE>
<TABLE COLS="4" ROWS="15">
<TR>
<TD>
<P>Search</P>
</TD>
<TD>
<P>Most Recent Queries</P>
</TD>
<TD>
<P>Time</P>
</TD>
<TD>
<P>Result</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?querykey=22&amp;dbase=pubmed&amp;tab=History&amp;querytype=eSearch&amp;">#22</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search (#18 AND #19) NOT (animals [mh] NOT human [mh]) Limits: Publication Date from 1995/01/01 to 2009/07/15</P>
</TD>
<TD VALIGN="TOP">
<P>13:32:19</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=HistorySearch&amp;querykey=22&amp;tab=&amp;">617</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?querykey=21&amp;dbase=pubmed&amp;tab=History&amp;querytype=eSearch&amp;">#21</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search (#18 AND #19) NOT (animals [mh] NOT human [mh])</P>
</TD>
<TD VALIGN="TOP">
<P>13:26:51</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=HistorySearch&amp;querykey=21&amp;tab=&amp;">624</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?querykey=20&amp;dbase=pubmed&amp;tab=History&amp;querytype=eSearch&amp;">#20</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search #18 AND #19</P>
</TD>
<TD VALIGN="TOP">
<P>13:24:02</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=HistorySearch&amp;querykey=20&amp;tab=&amp;">626</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?querykey=19&amp;dbase=pubmed&amp;tab=History&amp;querytype=eSearch&amp;">#19</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search (zidovudine OR lamivudine OR stavudine or didanosine OR emtricitabine OR nevirapine OR efavirenz OR tenofovir OR abacavir OR atazanavir OR lopinavir/ritonavir OR darunavir OR fosamprenavir OR indinavir OR saquinavir OR ritonavir OR nelfinavir OR tipranavir OR Trizivir OR Combivir OR Kaletra OR Truvada OR Duovir OR Viraday OR Triomune OR Odivir)</P>
</TD>
<TD VALIGN="TOP">
<P>13:20:10</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=HistorySearch&amp;querykey=19&amp;tab=&amp;">23441</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?querykey=18&amp;dbase=pubmed&amp;tab=History&amp;querytype=eSearch&amp;">#18</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search #3 AND #16 AND #17</P>
</TD>
<TD VALIGN="TOP">
<P>10:07:57</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=HistorySearch&amp;querykey=18&amp;tab=&amp;">1473</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?querykey=17&amp;dbase=pubmed&amp;tab=History&amp;querytype=eSearch&amp;">#17</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search TREATMENT FAILURE</P>
</TD>
<TD VALIGN="TOP">
<P>10:07:35</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=HistorySearch&amp;querykey=17&amp;tab=&amp;">153495</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?querykey=16&amp;dbase=pubmed&amp;tab=History&amp;querytype=eSearch&amp;">#16</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search #10 OR #11 OR #12 OR #15</P>
</TD>
<TD VALIGN="TOP">
<P>10:06:53</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=HistorySearch&amp;querykey=16&amp;tab=&amp;">347813</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?querykey=15&amp;dbase=pubmed&amp;tab=History&amp;querytype=eSearch&amp;">#15</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search MEDICATION ADHERENCE OR ADHERENCE</P>
</TD>
<TD VALIGN="TOP">
<P>10:05:56</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=HistorySearch&amp;querykey=15&amp;tab=&amp;">53496</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?querykey=12&amp;dbase=pubmed&amp;tab=History&amp;querytype=eSearch&amp;">#12</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search (SECOND-LINE THERAPY) OR (SECOND-LINE TREATMENT) OR (SECOND-LINE ANTIRETROVIRAL THERAPY) OR (SECOND-LINE ANTIRETROVIRAL TREATMENT)</P>
</TD>
<TD VALIGN="TOP">
<P>10:03:31</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=HistorySearch&amp;querykey=12&amp;tab=&amp;">6787</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?querykey=11&amp;dbase=pubmed&amp;tab=History&amp;querytype=eSearch&amp;">#11</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search SALVAGE THERAPY</P>
</TD>
<TD VALIGN="TOP">
<P>10:01:29</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=HistorySearch&amp;querykey=11&amp;tab=&amp;">14918</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?querykey=10&amp;dbase=pubmed&amp;tab=History&amp;querytype=eSearch&amp;">#10</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search (DRUG RESISTANCE) OR (DRUG RESISTANCE, VIRAL) OR (ANTIVIRAL DRUG RESISTANCE) OR (ANTIVIRAL DRUG RESISTANCES)</P>
</TD>
<TD VALIGN="TOP">
<P>10:01:15</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=HistorySearch&amp;querykey=10&amp;tab=&amp;">277283</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?querykey=3&amp;dbase=pubmed&amp;tab=History&amp;querytype=eSearch&amp;">#3</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search #1 AND #2</P>
</TD>
<TD VALIGN="TOP">
<P>09:50:43</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=HistorySearch&amp;querykey=3&amp;tab=&amp;">66143</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?querykey=2&amp;dbase=pubmed&amp;tab=History&amp;querytype=eSearch&amp;">#2</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search Antiretroviral Therapy, Highly Active[MeSH] OR Anti-Retroviral Agents[MeSH] OR Antiviral Agents[MeSH:NoExp] OR ((anti) AND (hiv[tw])) OR antiretroviral*[tw] OR ((anti) AND (retroviral*[tw])) OR HAART[tw] OR ((anti) AND (acquired immunodeficiency[tw])) OR ((anti) AND (acquired immunedeficiency[tw])) OR ((anti) AND (acquired immuno-deficiency[tw])) OR ((anti) AND (acquired immune-deficiency[tw])) OR ((anti) AND (acquired immun*) AND (deficiency[tw]))</P>
</TD>
<TD VALIGN="TOP">
<P>09:49:48</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=HistorySearch&amp;querykey=2&amp;tab=&amp;">99298</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?querykey=1&amp;dbase=pubmed&amp;tab=History&amp;querytype=eSearch&amp;">#1</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search HIV Infections[MeSH] OR HIV[MeSH] OR hiv[tw] OR hiv-1*[tw] OR hiv-2*[tw] OR hiv1[tw] OR hiv2[tw] OR hiv infect*[tw] OR human immunodeficiency virus[tw] OR human immunedeficiency virus[tw] OR human immuno-deficiency virus[tw] OR human immune-deficiency virus[tw] OR ((human immun*) AND (deficiency virus[tw])) OR acquired immunodeficiency syndrome[tw] OR acquired immunedeficiency syndrome[tw] OR acquired immuno-deficiency syndrome[tw] OR acquired immune-deficiency syndrome[tw] OR ((acquired immun*) AND (deficiency syndrome[tw])) OR "sexually transmitted diseases, viral"[MH]</P>
</TD>
<TD VALIGN="TOP">
<P>09:49:32</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=HistorySearch&amp;querykey=1&amp;tab=&amp;">253117</A>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2010-05-12 14:57:41 -0700" MODIFIED_BY="Tara Horvath" NO="2">
<TITLE MODIFIED="2010-04-27 11:19:16 -0700" MODIFIED_BY="[Empty name]">Newcastle Ottawa Scale</TITLE>
<TABLE COLS="4" ROWS="11">
<TR>
<TD>
<P>Item</P>
</TD>
<TD>
<P>Hull 2009</P>
</TD>
<TD>
<P>Murphy 2008</P>
</TD>
<TD>
<P>Pujades Rodriguez 2008</P>
</TD>
</TR>
<TR>
<TD>
<P>Representativeness of cohort</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>Selection of nonexposed cohort</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>Ascertainment of Cohort</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>Outcome of interest not present at start of study</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>Comparability of cohorts 1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>Comparability of cohorts 2</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>2</P>
</TD>
</TR>
<TR>
<TD>
<P>Assessment of outcome</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>Long enough follow-up</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>Adequacy of follow-up</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>TOTAL</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>7</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-05-03 06:03:50 -0700" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2010-05-03 06:03:50 -0700" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Maintaining lamivudine or not</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-01-19 11:53:47 -0800" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>mortality</NAME>
<GROUP_LABEL_1>3TC</GROUP_LABEL_1>
<GROUP_LABEL_2>No 3TC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-01-19 11:54:14 -0800" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Disease progression</NAME>
<GROUP_LABEL_1>3TC</GROUP_LABEL_1>
<GROUP_LABEL_2>No 3TC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-01-19 11:54:32 -0800" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>3TC</GROUP_LABEL_1>
<GROUP_LABEL_2>No 3TC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-01-19 12:03:56 -0800" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adherence/tolerability/retention</NAME>
<GROUP_LABEL_1>3TC</GROUP_LABEL_1>
<GROUP_LABEL_2>No 3TC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7969228763140799" CI_START="0.9205691227936703" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2861538461538462" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.25452943764876446" LOG_CI_START="-0.035943596056442796" LOG_EFFECT_SIZE="0.10929292079616083" METHOD="MH" MODIFIED="2010-01-19 12:03:56 -0800" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.14023785700531968" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="65" TOTAL_2="66" WEIGHT="100.0" Z="1.474905851281601">
<NAME>Proportion achieving viral suppression</NAME>
<GROUP_LABEL_1>3TC</GROUP_LABEL_1>
<GROUP_LABEL_2>No 3TC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7969228763140799" CI_START="0.9205691227936703" EFFECT_SIZE="1.2861538461538462" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="30" LOG_CI_END="0.25452943764876446" LOG_CI_START="-0.035943596056442796" LOG_EFFECT_SIZE="0.10929292079616083" MODIFIED="2010-01-19 11:56:22 -0800" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.17062529786314515" STUDY_ID="STD-Fox-2006" TOTAL_1="65" TOTAL_2="66" VAR="0.029112992270887005" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="32.09330623830971" CI_START="-10.093306238309708" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="11.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2010-05-03 06:03:50 -0700" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.3067305468099" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="65" TOTAL_2="66" UNITS="" WEIGHT="100.0" Z="1.0221064249654708">
<NAME>immunologic outcome</NAME>
<GROUP_LABEL_1>3TC</GROUP_LABEL_1>
<GROUP_LABEL_2>No 3TC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="32.09330623830971" CI_START="-10.093306238309708" EFFECT_SIZE="11.0" ESTIMABLE="YES" MEAN_1="88.0" MEAN_2="77.0" MODIFIED="2010-05-03 06:03:50 -0700" MODIFIED_BY="[Empty name]" ORDER="2" SD_1="58.49" SD_2="64.58" SE="10.762088693818363" STUDY_ID="STD-Fox-2006" TOTAL_1="65" TOTAL_2="66" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2010-05-03 06:03:51 -0700" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Eliza Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2010-01-14 06:29:55 -0800" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Flow Chart Search Results</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAd0AAAK2CAIAAACEhNE9AACAAElEQVR42uy9ebyO1f7/L0WDSpOG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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2010-04-27 11:25:08 -0700" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAVYAAAFiCAIAAAAiJmdvAAAPOklEQVR42u3dv24dRRTH8SvRULhw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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2010-04-27 11:25:09 -0700" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAfMAAADnCAMAAAA94U9AAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2010-04-27 11:25:09 -0700" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.05" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Maintaining lamivudine or not, outcome: 1.5 Proportion achieving viral suppression.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAr4AAACQCAMAAADZYJgoAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2010-05-03 06:03:51 -0700" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.06" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Maintaining lamivudine or not, outcome: 1.6 immunologic outcome.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAw8AAACACAMAAAB6DKV0AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2010-05-12 09:46:10 -0700" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2010-05-12 09:46:10 -0700" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-07-11 09:52:49 -0700" MODIFIED_BY="[Empty name]">Newcastle-Ottawa quality assessment scale for cohort studies.</TITLE>
<APPENDIX_BODY MODIFIED="2010-05-12 09:46:10 -0700" MODIFIED_BY="[Empty name]">
<P>
<U>Note</U>: A study can be awarded a maximum of one star (*) for each numbered item within the Selection and Outcome categories. A maximum of two stars can be given for Comparability.</P>
<P>
<B> </B>
</P>
<P>
<B>Selection</B>
</P>
<P>1) <U>Representativeness of the exposed cohort</U>
</P>
<P>a) truly representative of the average _______________ (describe) in the community *</P>
<P>b) somewhat representative of the average ______________ in the community *</P>
<P>c) selected group of users, e.g. nurses, volunteers</P>
<P>d) no description of the derivation of the cohort</P>
<P>2) <U>Selection of the non exposed cohort</U>
</P>
<P>a) drawn from the same community as the exposed cohort *</P>
<P>b) drawn from a different source</P>
<P>c) no description of the derivation of the non exposed cohort           </P>
<P>3) <U>Ascertainment of exposure</U>
</P>
<P>a) secure record (e.g. surgical records) *</P>
<P>b) structured interview</P>
<P>c) written self report</P>
<P>d) no description</P>
<P>4) <U>Demonstration that outcome of interest was not present at start of study</U>
</P>
<P>a) yes *</P>
<P>b) no</P>
<P> </P>
<P>
<B>Comparability</B>
</P>
<P>1) <U>Comparability of cohorts on the basis of the design or analysis</U>
</P>
<P>a) study controls for _____________ (select the most important factor) *</P>
<P>b) study controls for any additional factor Ç  (This criteria could be modified to indicate specific control for a second important factor.)           </P>
<P> </P>
<P>
<B>Outcome</B>
</P>
<P>1) <U>Assessment of outcome</U>
</P>
<P>a) independent blind assessment *</P>
<P>b) record linkage *</P>
<P>c) self report           </P>
<P>d) no description</P>
<P>2) <U>Was follow-up long enough for outcomes to occur</U>
</P>
<P>a) yes (select an adequate follow-up period for outcome of interest) *</P>
<P>b) no</P>
<P>3) <U>Adequacy of follow-up of cohorts</U>
</P>
<P>a) complete follow-up - all subjects accounted for *</P>
<P>b) subjects lost to follow-up unlikely to introduce bias</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2010-01-12 07:58:14 -0800" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-07-11 09:54:46 -0700" MODIFIED_BY="[Empty name]">GRADE approach to assessing the quality of evidence across studies</TITLE>
<APPENDIX_BODY MODIFIED="2009-07-11 09:55:14 -0700" MODIFIED_BY="[Empty name]">
<TABLE COLS="4" ROWS="5">
<TR>
<TD>
<P>
<B>Quality of Evidence</B>
</P>
<P>
<B>(summary score)</B>
</P>
</TD>
<TD>
<P>
<B>Study Design</B>
</P>
</TD>
<TD>
<P>
<B>Downgrading Factors</B>
</P>
</TD>
<TD>
<P>
<B>Upgrading Factors</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>High (4)</B> = Further research is very unlikely to change our confidence in the estimate of effect.</P>
</TD>
<TD>
<P>Randomized trials or valid accuracy studies for  diagnostic tests begin with a score of High (4)</P>
</TD>
<TD ROWSPAN="4">
<P>
<B>Study limitations:</B>
</P>
<P>-1 Serious</P>
<P>-2 Very serious</P>
<P> </P>
<P>
<B>Consistency:</B>
</P>
<P>-1 Serious</P>
<P>-2 Very serious</P>
<P> </P>
<P>
<B>Directness:</B>
</P>
<P>-1 Serious</P>
<P>-2 Very serious</P>
<P> </P>
<P>
<B>Precision:</B>
</P>
<P>-1 Serious</P>
<P>-2 Very serious</P>
<P> </P>
<P>
<B>Publication Bias</B>
</P>
<P>-1 Serious</P>
<P>-2 Very serious</P>
</TD>
<TD ROWSPAN="4">
<P>
<B>Large effect</B>
</P>
<P>+1 Large</P>
<P>+2 Very Large</P>
<P>
<B> </B>
</P>
<P>
<B>Plausible confounding would change the effect</B>
</P>
<P>+1</P>
<P>
<B> </B>
</P>
<P>
<B>Dose-response gradient</B>
</P>
<P>+1 if Present</P>
<P>
<B> </B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Moderate (3)</B> = Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Low (2)</B> = Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.</P>
</TD>
<TD>
<P>Observational studies or indirect accuracy studies for diagnostic tests begin with a score of low (2).</P>
<P>
<B> </B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Very low (1)</B> = Any estimate of effect is very uncertain.</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2010-05-12 09:45:13 -0700" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2010-04-15 08:33:02 -0700" MODIFIED_BY="[Empty name]">WHO 2009 Rapid Advice: antiretroviral therapy for HIV infection in adults and adolescents, recommendations on second-line ART</TITLE>
<APPENDIX_BODY MODIFIED="2010-05-12 09:45:13 -0700" MODIFIED_BY="[Empty name]">
<P>
<U>When to switch ART</U>
<BR/>1. Where available, use viral load (VL) to confirm treatment failure.<BR/>(Strong recommendation, low quality of evidence)</P>
<P>
<BR/>2. Where routinely available, use VL every 6 months to detect viral replication.<BR/>(Conditional recommendation, low quality of evidence)</P>
<P>
<BR/>3. A persistent VL above 5,000 copies/mL confirms treatment failure.<BR/>(Conditional recommendation, low quality of evidence)<BR/>
</P>
<P>4. When VL is not available, use immunological criteria to confirm clinical failure.<BR/>(Strong recommendation, moderate quality of evidence)</P>
<P>
<U>Second-line ART</U>
<BR/>1. A boosted protease inhibitor (PI/r) plus two nucleoside analogues (NRTIs) are recommended for second-line ART. (Strong recommendation, moderate quality of evidence)<BR/>
</P>
<P>2. ATV/r and LPV/r are the preferred boosted PI&#8217;s for second-line ART.<BR/>(Strong recommendation, moderate quality of evidence)<BR/>
</P>
<P>3. Simplification of second NRTI options is recommended.<BR/>&#8226; If d4Tor AZT has been used in first-line, use TDF+3TC or FTC as the NRTI backbone in second-line.<BR/>&#8226; If TDF has been used in first-line, use AZT+3TC as the NRTI backbone in second-line.<BR/>(Strong recommendation, moderate quality of evidence)<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>